WO2018200489A1 - Il-8, il-6, il-1b et tet2 et dnmt3a dans l'athérosclérose - Google Patents

Il-8, il-6, il-1b et tet2 et dnmt3a dans l'athérosclérose Download PDF

Info

Publication number
WO2018200489A1
WO2018200489A1 PCT/US2018/029098 US2018029098W WO2018200489A1 WO 2018200489 A1 WO2018200489 A1 WO 2018200489A1 US 2018029098 W US2018029098 W US 2018029098W WO 2018200489 A1 WO2018200489 A1 WO 2018200489A1
Authority
WO
WIPO (PCT)
Prior art keywords
tet2
dnmt3a
subject
mutation
inhibitor
Prior art date
Application number
PCT/US2018/029098
Other languages
English (en)
Inventor
Jaiswal SIDDHARTHA
Sekar Kathiresan
Benjamin Ebert
Original Assignee
The Brigham And Women’S Hospital, Inc.
The General Hospital Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham And Women’S Hospital, Inc., The General Hospital Corp. filed Critical The Brigham And Women’S Hospital, Inc.
Priority to US16/606,928 priority Critical patent/US20200131576A1/en
Priority to EP18727474.1A priority patent/EP3615694B1/fr
Publication of WO2018200489A1 publication Critical patent/WO2018200489A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • Clonal hematopoiesis of indeterminate potential (CHIP), defined by the presence of an expanded somatic blood cell clone in those without other hematologic abnormalities, is common in older individuals and associates with an increased risk of developing hematologic cancer.
  • somatic TET2 and/or DNMT3A mutations in blood cells and atherosclerosis has also been demonstrated. However, the nature of this association was unclear and these mutations were not previously known to be associated with increased IL-8, IL-6, IL- ⁇ ⁇ levels or a need to inhibit IL-8 activity.
  • a new method of treating and diagnosing atherosclerosis is now warranted, relying on the presence of both at least one TET2 and/or DNMT3A mutation and elevated IL-8 levels.
  • the present inventors have found that individuals with CHIP are at increased risk for all-cause mortality and, surprisingly, for developing coronary heart disease. While traditional risk factors such as hypercholesterolemia, type 2 diabetes, hypertension, and smoking account for a large proportion of the risk for coronary heart disease, some individuals who develop coronary heart disease lack known risk factors, suggesting that unknown factors may also contribute to atherosclerotic complications.
  • Hyperlipidemic mice engrafted with Tet2-I- or Tet2+I- bone marrow developed larger atherosclerotic lesions in the aortic root and aorta than mice receiving control marrow.
  • clonal hematopoiesis associates with coronary heart disease in humans and causes accelerated atherosclerosis in a mouse model.
  • TET2 mutations as well as those in DNMT3A, ASXL1, and JAK2, individually associate with risk of coronary heart disease in at least one set of human cohorts.
  • a method of treating atherosclerosis in a human subject comprises administering an effective amount of at least one IL-8 inhibitor, IL-6 inhibitor, and/or IL- ⁇ inhibitor, wherein the subject has a TET2 and/or DNMT3A mutation, thereby treating atherosclerosis.
  • a method for treating atherosclerosis in a human subject comprises (a) sequencing at least a part of a genome comprising TET2 and/or DNMT3A of one or more cells in a blood sample of the subject; (b) determining from the sequencing whether the subject has one or more mutations in TET2 and/or DNMT3A, and (c) if it is determined that the subject has at least one TET2 and/or DNMT3A mutation, administering at least one IL-8 inhibitor to the subject thereby treating atherosclerosis.
  • a method of treating atherosclerosis in a human subject comprises administering an effective amount of at least one IL-8 inhibitor, IL-6 inhibitor, and/or IL- ⁇ inhibitor, wherein the subject's plasma IL-8 level is at least 20 ng/mL thereby treating atherosclerosis.
  • a method for treating atherosclerosis in a human subject comprises (a) determining from a plasma sample whether the subject has an increased level of plasma IL-8 and (b) if it is determined that the subject has an IL-8 level of at least 20 ng/mL, administering an effective amount of at least one IL-8 inhibitor to a subject to the subject thereby treating atherosclerosis.
  • the method further comprises administering an effective amount of at least one cholesterol-lowering medication to the subject.
  • the method further comprises prescribing exercise, cessation of smoking, diet modification, and/or stress reduction to the subject.
  • a method for diagnosing atherosclerosis in a human subject comprises: (a) determining whether the subject has an increased level of plasma IL-8, wherein the level of IL-8 is at least 20 ng/mL and (b) diagnosing the subject as having atherosclerosis when an increased level of IL-8 of at least 20 ng/mL is detected.
  • the method further comprises detecting whether the sample contains at least one TET2 and/or DNMT3A mutation with a probe of sufficient length and composition to detect a TET2 and/or DNMT3A mutation; and diagnosing the subject as having atherosclerosis when at least one TET2 and/or DNMT3A mutation is detected.
  • a method of detecting at least one TET2 and/or DNMT3A mutation along with an increase in plasma level of IL-8 in a human subject comprises obtaining a nucleic acid sample from the subject; detecting whether the sample contains at least one TET2 and/or DNMT3A mutation with a probe of sufficient length and composition to detect a TET2 and/or DNMT3A mutation; obtaining a plasma sample from the subject; determining whether the subject has an increased level of plasma IL-8, wherein the level of IL-8 is at least 20 ng/mL.
  • the at least one TET2 and/or DNMT3A mutation comprises a frameshift mutation, nonsense mutation, missense mutation, or splice-site variant mutation. In some embodiments, the at least one TET2 and/or DNMT3A mutation comprises at least one loss-of-function TET2 and/or DNMT3A mutation.
  • the mutation in TET2 results in an amino acid change in TET2 chosen from S145N, S282F, A308T, N312S, L346P, P399L, S460F, D666G, S817T, P941 S, C1135Y, R1167T, I1175V, S 1204C, R1214W, D1242R, D1242V, Y1245S, R1261C, R1261H, R1261L, F1287L, W1291R, K1299E, K1299N, R1302G, E1318G, P1367S, C1396W, L1398R, V1417F, G1869W, L1872P, I1873T, C1875R, H1881Q, H1881R, R1896M, R1896S, S1898F, V1900A, G1913D, A1919V, R1926H, P1941 S, P1962L, R1966
  • the mutation in DNMT3A results in an amino acid change in DNMT3A chosen from F290I, F290C, V296M, P307S, P307R, R326H, R326L, R326C, R326S, G332R, G332E, V339A, V339M, V339G, L344Q, L344P, R366P, R366H, R366G, A368T, A368V, R379H, R379C, I407T, I407N, I407S, F414L, F414S, F414C, A462V, K468R, C497G, C497Y, Q527H, Q527P, Y533C, S535F, C537G, C537R, G543A, G543S, G543C, L547H, L547P, L547F,
  • the human subject has at least one somatic blood cell clone with one mutant TET2 allele and one wildtype TET2 allele. In some embodiments, the human subject has at least one somatic blood cell clone with two mutant TET2 alleles. In some aspects, the human subject has at least one somatic blood cell clone with one mutant DNMT3A allele and one wildtype DNMT3A allele. In some embodiments, the human subject has at least one somatic blood cell clone with two mutant DNMT3A alleles. In some embodiments, the human subject has clonal hematopoiesis of indeterminate potential (CHIP).
  • CHIP indeterminate potential
  • the human subject may have at least one TET2 and/or DNMT3A mutation in at least 5%, 10%, 13.5%, 15%, 20%, 25%, 27%, 30% of nucleated peripheral blood cells.
  • the human subject may also have a plasma level of IL-8 that is at least 25 ng/mL, 30 ng/mL, 40 ng/mL, 45 ng/mL, 50 ng/mL, 55 ng/mL, 60 ng/mL, 65 ng/mL, 70 ng/mL, 75 ng/mL, or 80 ng/mL.
  • the at least one IL-6 inhibitor and/or IL- ⁇ inhibitor is methotrexate.
  • the methotrexate is administered at a dose of from 15 to 20 mg/week.
  • the at least one IL-8 inhibitor is an IL-8 depleting drug. In some embodiments, the at least one IL-8 inhibitor is an IL-8 activity reducing drug. In some embodiments, the at least one IL-8 inhibitor comprises an anti-IL-8 antibody or an antigen binding fragment thereof. In some embodiments, the anti-IL-8 antibody or antigen binding fragment thereof comprises HuMaxIL-8, HuMab-10F8, or an antigen binding fragment thereof. In some embodiments, the at least one IL-8 inhibitor is an inhibitor of the IL-8 receptor CXCR2. In some embodiments, the at least one IL-8 inhibitor comprises an anti-CXCR2 antibody or an antigen binding fragment thereof. In some embodiments, the at least one IL-8 inhibitor comprises the CXCR2 inhibitor SB-332235 (GlaxoSmithKline).
  • the IL-6 inhibitor is an IL-6 depleting drug. In some embodiments, the IL-6 inhibitor is an IL-6 activity reducing drug. In some embodiments, the IL- 6 inhibitor comprises an anti-IL-6 antibody or an antigen binding fragment thereof. In some embodiments, the anti-IL-6 antibody or antigen binding fragment thereof comprises siltuximab, olokizumab, elsilimomab, mAb 1339, BMS-945429, sirukumab, CPSI-2364, ALX-0061, clazakizumab, ARGX-109, MEDI5117, FE301, FM101, or C326.
  • the at least one IL-6 inhibitor is an inhibitor of the IL-6 receptor IL-6R or an inhibitor of gpl30.
  • the inhibitor of IL-6R comprises tocilizumab or sarilumab.
  • the IL-6 inhibitor comprises tamibarotene or ATRA.
  • the IL- ⁇ ⁇ inhibitor is an IL- ⁇ ⁇ depleting drug. In some embodiments, the IL- ⁇ inhibitor is an IL- ⁇ ⁇ activity reducing drug. In some embodiments, the IL- ⁇ inhibitor comprises an anti- IL- ⁇ ⁇ antibody or antigen binding fragment thereof. In some embodiments, the anti-IL- ⁇ ⁇ antibody or antigen binding fragment thereof comprises canakinumab. In some embodiments, the IL- ⁇ ⁇ inhibitor is an inhibitor of the IL- ⁇ ⁇ receptor. In some embodiments, the IL- ⁇ inhibitor is an inhibitor of IL-1 receptor. In some embodiments, the inhibitor of the IL-1 receptor is anakinra.
  • At least one cholesterol-lowering medication comprises at least one PCSK9 inhibitor, at least one statin, at least one selective cholesterol absorption inhibitor, at least one resin, at least one lipid-lowering therapy, at least one CETP inhibitor, at least one pantothenic acid derivative, at least one microsomal triglyceride transfer protein (MTP) inhibitor, at least one adenosine triphosphate-binding cassette transporter Al (ABCA1)- promoter, aspirin, estrogen, and/or at least one lipoprotein complex.
  • PCSK9 inhibitor at least one statin
  • at least one selective cholesterol absorption inhibitor at least one resin
  • MTP microsomal triglyceride transfer protein
  • ABCA1 adenosine triphosphate-binding cassette transporter Al
  • the cholesterol-lowering medication comprises at least one PCSK9 inhibitor.
  • the PCSK9 inhibitor is chosen from at least one of
  • an anti-PC SK9 antibody or antigen-binding fragment thereof (i) an anti-PC SK9 antibody or antigen-binding fragment thereof, (ii) an antisense or RNAi therapeutic agent that inhibits the synthesis of PCSK9, (ii) a PCSK9-targeting vaccine.
  • the anti-PCSK9 antibody or antigen-binding fragment thereof is evolocumab, alirocumab, bococizumab, LGT209, RG7652, or LY3015014.
  • the RNAi therapeutic agent that inhibits the synthesis of PCSK9 is inclisiran.
  • the PCSK9-targeting vaccine is AT04A or AT06A.
  • the PCSK9 inhibitor is a polypeptide that binds PCSK9 (such as adnectin).
  • the PCSK9 inhibitor is a locked nucleic acid targeting PCSK9 (such as SPC5001).
  • the PCSK9 inhibitor is an antisense RNA that inhibits the synthesis of PCSK9 is ISIS-405879/BMS-844421.
  • the cholesterol-lowering medication comprises at least one statin.
  • the statin is chosen from at least one of atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and pitavastatin.
  • the statin comprises a combination therapy chosen from (i) lovastatin and niacin,
  • the cholesterol-lowering medication comprises at least one selective cholesterol absorption inhibitor.
  • the selective cholesterol absorption inhibitor is ezetimibe.
  • the cholesterol-lowering medication comprises at least one resin.
  • the resin is chosen from cholestyramine, colestipol, and colesevelam.
  • the cholesterol-lowering medication comprises at least one lipid-lowering therapy.
  • the lipid-lowering therapy is chosen from at least one fibrate, niacin, and at least one omega-3 fatty acid.
  • the lipid- lowering therapy comprises at least one fibrate.
  • the fibrate is chosen from gemfibrozil, fenofibrate, and clofibrate.
  • the lipid-lowering therapy comprises at least one omega-3 fatty acid.
  • the omega-3 fatty acid is chosen from at least one of omega-3 fatty acid ethyl esters and omega-3 polyunsaturated fatty acids.
  • the omega-3 fatty acid ethyl esters are icosapent ethyl.
  • the omega-3 polyunsaturated fatty acids are marine-derived omega-3
  • the cholesterol-lowering medication comprises a CETP inhibitor.
  • the CETP inhibitor is chosen from at least one of anacetrapib and obicetrapib.
  • the cholesterol-lowering medication comprises at least one MTP inhibitor.
  • the MTP inhibitor is chosen from at least one of (i) a small molecule that inhibits function of MTP, (ii) an RNAi therapeutic agent that inhibits the synthesis of MTP, and (iii) an antisense RNA that inhibits synthesis of MTP.
  • the small molecule that inhibits function of MTP is chosen from at least one of lomitapide, JTT-130, Slx-4090, and dirlotapide.
  • the cholesterol-lowering medication comprises adenosine triphosphate-binding cassette transporter Al (ABCAl)-promoter.
  • the adenosine triphosphate-binding cassette transporter Al (ABCAl)-promoting drug is chosen from at least one of (i) an apoA-1 mimetic peptide, (ii) a full-length apoA-1, and (iii) a reconstituted HDL.
  • the apoA-1 mimetic peptide is FAMP type 5
  • the full-length apoA-1 is ApoA-l-Milano or ETC-216.
  • the cholesterol-lowering medication comprises estrogen.
  • the cholesterol-lowering medication comprises at least one lipoprotein complex.
  • the lipoprotein complex is chosen from at least one of CER-001, CSL- 111, CSL-112, and ETC-216.
  • the lipoprotein complex is chosen from at least one of apolipoprotein or apolipoprotein peptide mimic.
  • the (i) apolipoprotein is chosen from at least one of ApoA-I, ApoA-II, ApoA-IV, and ApoE and/or (ii) the peptide mimetic is chosen from at least one of ApoA-I, ApoA-II, ApoA-IV, and ApoE peptide mimic.
  • the human subject also exhibits one or more risk factors of being a smoker, having level of total cholesterol of at least 200 mg/dL, or having level of low- density lipoprotein (LDL) of at least 130 mg/dL.
  • LDL low- density lipoprotein
  • the human subject has a total cholesterol of at least 240 mg/dL and/or an LDL of at least 160 mg/dL.
  • the human subject has elevated hsCRP and optionally an hsCRP level of at least 2 mg/L.
  • the method comprises prescribing exercise. In some embodiments, the method comprises prescribing exercise for at least 3, 4, 5, 6, or 7 days a week. In some embodiments, the method comprises prescribing cardiovascular conditioning exercise. In some embodiments, the method comprises prescribing strength training exercise. In some embodiments, the method comprises prescribing cessation of smoking. In some embodiments, the method comprises administering a medication to support smoking cessation. In some embodiments, the medication to support smoking cessation is chosen from at least one of nicotine replacement therapy, antidepressants (such as bupropion, nortriptyline, or an SSRI), varenicline, and clonidine.
  • antidepressants such as bupropion, nortriptyline, or an SSRI
  • varenicline varenicline
  • clonidine clonidine
  • the method comprises diet modification.
  • the diet modification is chosen from at least one of a reduction in fat
  • the method comprises stress reduction.
  • the stress reduction is chosen from at least one of relaxation techniques, mediation, breathing exercises, exercise, and/or anger management.
  • the method comprises prescribing psychiatric medication.
  • the method comprises anti-anxiety medication and/or anti-depressant medication.
  • the anti-anxiety medication and/or anti-depressant medication is chosen from at least one of citalopram, escitalopram, fluoxetine, paroxetine, sertraline, duloxetine, venlafaxine, imipramine, hydroxyzine, propanolol, gabapentin, and pregabalin.
  • the method comprises prescribing psychological counseling.
  • the TET2 and/or DNMT3A mutation is identified by whole exome sequencing (WES). In some embodiments, TET2 and/or DNMT3A mutation is identified by sequencing DNA.
  • Figures 1A-1B show variant characteristics in Bioimage and MDC studies. A) Top 10 most frequently mutated genes. Total number of variants per gene is listed. B)
  • Figures 2A-2D show that CHIP associates with coronary heart disease.
  • Odds ratio for MI risk was obtained by a logistic regression model adjusted for age, sex, type 2 diabetes, smoking status.
  • CHIP clonal hematopoiesis of indeterminate potential
  • CHD coronary heart disease
  • HR hazard ratio
  • MDC Methylcholine
  • VAF variable allele fraction
  • MI myocardial infarction
  • OR odds ratio
  • ATVB AtVB (Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group).
  • Figures 3A-3B show mutations in DNMT3A, TET2, ASXL1, and JAK2 associate with coronary heart disease.
  • Hazard ratio for listed mutations was obtained by a Cox proportional hazards model adjusted for age, sex, type 2 diabetes, total cholesterol, high-density lipoprotein cholesterol, smoking status, and hypertension.
  • Figure 4 shows coronary artery calcification by variant allele fraction (VAF) in those with and without incident CHD.
  • Horizontal bar represents the median value for coronary artery calcification score plus 1. The median value for each group is also listed above each plot.
  • FIGS 5A-5B show that CHIP is associated with subclinical atherosclerosis in humans.
  • Odds ratio was obtained by a logistic regression model adjusted for age, sex, type 2 diabetes, total cholesterol, high-density lipoprotein cholesterol, smoking status, and hypertension.
  • CAC coronary artery calcification
  • VAF variable allele fraction
  • Figures 6A-6E show that loss of Tet2 in hematopoietic cells accelerates atherosclerosis in a mouse model.
  • Figures 7A-7C show gene-expression analysis of Tet2-/- bone marrow derived macrophages.
  • A) BMDM were cultured with 200 mg/dL native low density lipoprotein (LDL) or vehicle for 24 hours and messenger RNA was assessed by RNA-sequencing. At a false discovery rate of q ⁇ 0.05, 2090 genes were differentially expressed by genotype (Tet2+/+ versus Tet2-/- ⁇ 479 genes differentially expressed by LDL treatment, and 217 genes were differentially expressed by both variables.
  • FIGS 8A-8C show that Tet2 deficiency causes dysregulated chemokine expression in macrophages in vitro and in vivo.
  • Figures 9A-9C show chemokine expression related to Tet2 deficiency.
  • BMDM were cultured with 200 mg/dL native low density lipoprotein (LDL) or vehicle for 24 hours and messenger RNA was assessed by RNA-sequencing. Shown are normalized reads counts per sample for select genes.
  • B) BMDM were cultured with 200 mg/dL native LDL, 10 ng/mL lipopolysaccharide (LPS), or vehicle for 24 hours and protein secretion was measured in the cell culture supernatant. Tet2+/+ macrophage supernatant is shown in left-hand groups for each treatment, and Tet2-/- is shown in right-hand groups for each treatment. P-values by Welch's t-test, only values less than 0.05 are shown. Four biological replicates per treatment are shown.
  • FIG. 10 shows IL-8, CXCL1, and CXCL2 levels in control cells and cells modified by CRISPR to express TET2 mutations. IL-8 and CXCL2 levels were higher in the cells with TET2 mutations.
  • FIG 11 shows representative sections from an experiment where Ldlr-I- mice were lethally irradiated and transplanted with either Dnmt3a+I+ (WT) or Dnmt3a+/- (HET) bone marrow. After 10 weeks on high cholesterol diet, lesions in the aortic root were assessed.
  • WT Dnmt3a+I+
  • HET Dnmt3a+/-
  • Figure 12 shows quantitative assessment of aortic root lesion size from an experiment where Ldlr-I- mice were lethally irradiated and transplanted with either Dnmt3a+I+ (WT) or Dnmt3a+/- (HET) bone marrow. After 10 weeks on high cholesterol diet, lesions in the aortic root were assessed.
  • WT Dnmt3a+I+
  • HET Dnmt3a+/-
  • Figure 13 shows a plot of relative expression of genes by treatment with LDL (x- axis) and by genotype (y-axis).
  • BMDM from Dnmt3a+/+ or Dnmt3a-I- mice were loaded with vehicle or 200 mg/dL LDL and RNA sequencing was performed. Highlighted are 116, II lb, Cxcll, Cxcl2, and Cxcl3.
  • Figure 14 shows normalized read counts from an experiment where BMDM from Dnmt3a+/+ or Dnmt3ct-I- mice were loaded with vehicle or 200 mg/dL LDL and RNA sequencing was performed. Shown are normalized read counts for 116, II lb, Cxcll, Cxcl2, and Cxcl3.
  • Figure 15 shows protein levels from an experiment where BMDM from
  • Dnmt3a+/+ or Dnmt3ct-I- mice were loaded with vehicle or 200 mg/dL LDL and proteins secreted into the media were assessed by ELISA. Shown are protein levels for IL-6, IL- ⁇ ⁇ , Cxcll, Cxcl2, and Cxcl3.
  • FIGS 16A-16D show the size of aortic root lesions in wild-type and Dnmta deficient mice.
  • WT wild-type
  • KO knockout
  • the present application includes methods of treatment for atherosclerosis.
  • Atherosclerosis is the leading cause of death in the United States; however, little is known about non-lipid risk factors in humans.
  • This application relates to a mechanism behind the proposed causal association between somatic TET2 and/or DNMT3A mutations in blood cells, involvement of IL-8, IL-6, IL- ⁇ , and atherosclerosis.
  • TET2 and DNMT3A are enzymes that alters DNA methylation, it is likely that perturbing their function results in an abnormal epigenetic state. For example, TET2 converts 5- methylcytosine to 5-hydroxymethylcytosine, which ultimately leads to demethylation. As methylation at promoters and enhancers anti-correlates with gene expression and transcription factor binding, Applicants hypothesize that loss of TET2 function results in abnormal methylation of cis-regulatory elements for LXR/PPARG targets, reduced binding of
  • DNMT3A catalyzes the transfer of methyl groups to specific CpG structures in DNA and is responsible for de novo DNA methylation. How and why these alterations may lead to atherosclerosis is unknown. As these epigenetic marks are known to influence gene expression, we hypothesize that they lead to increased expression of inflammatory genes in macrophages, reduced expression of cholesterol metabolism genes in macrophages, or both.
  • a method of treating atherosclerosis in a human subject includes administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL- ⁇ ⁇ inhibitor wherein the subject has a TET2 and/or DNMT3A mutation, thereby treating atherosclerosis.
  • a method for treating atherosclerosis in a human subject comprises (a) sequencing at least a part of a genome comprising TET2 and/or DNMT3A of one or more cells in a blood sample of the subject; (b) determining from the sequencing whether the subject has one or more mutations in TET2, and/or DNMT3A and (c) if it is determined that the subject has at least one TET2 and/or DNMT3A mutation, administering an IL-8 inhibitor, an IL- 6 inhibitor, or an IL- ⁇ inhibitor, to the subject thereby treating atherosclerosis.
  • IL-8, IL-6, and/or IL- ⁇ status can be important to treatment.
  • a method of treating atherosclerosis in a human subject may, in some embodiments, comprise administering an effective amount of an IL-8 inhibitor, wherein the subject's plasma IL-8 level is at least 20 ng/mL thereby treating atherosclerosis.
  • Other levels or sources of IL-8 levels may be employed, as described in Section I.H below.
  • a method for treating atherosclerosis in a human subject may comprise (a) determining from a plasma sample whether the subject has an increased level of plasma IL-8, (b) if it is determined that the subject has an IL-8 level of at least 20 ng/mL, administering an effective amount of an IL-8 inhibitor to a subject to the subject thereby treating atherosclerosis.
  • Other levels or sources of IL-8 levels may be employed, as described in Section I.H below.
  • TET2 mutations may cause or be associated with atherosclerosis.
  • One or more than one TET2 mutation may be present in a somatic blood cell clone.
  • a TET2 mutation may be a frameshift mutation, a nonsense mutation, a missense mutation, or a splice-site variant mutation.
  • a TET2 mutation may also be a loss-of- function TET2 mutation.
  • a mutation in TET2 leads to non-expression or decreased expression of the TET2 protein or expression of a truncated or non-functional form of the TET2 protein. In some embodiments, a mutation in TET2 leads to a change in the structure or function of the TET2 protein.
  • the NM_001127208 sequence is a representative wild-type sequence of TET2.
  • the mutation in TET2 is a frameshift mutation.
  • the frameshift mutation is caused by insertion or deletion of a number of nucleotides that is not divisible by three.
  • the mutation in TET2 may also be an insertion or deletion of a number of nucleotides that is divisible by three, wherein one or more amino acids are added or deleted from the wild-type TET2 amino acid sequence.
  • the mutation in TET2 is a nonsense mutation.
  • the nonsense mutation is a point mutation (i.e., single nucleotide change) that results in a premature stop codon or a nonsense codon (i.e., a codon that does not code for an amino acid) in the transcribed RNA.
  • the nonsense mutation leads to a truncated, incomplete and/or nonfunctional TET2 protein.
  • the mutation in TET2 is a missense mutation.
  • the missense mutation is a point mutation that codes for a different amino acid than that found in the wildtype TET2 sequence.
  • the missense mutation is within nucleotides that encode one of the catalytic domains of the TET2 protein.
  • the missense mutation causes a change in amino acid from that encoded by the wildtype sequence at amino acids 1104-1481 or 1843-2002 of the TET2 protein.
  • the mutation in TET2 results in an amino acid change in TET2 chosen from S145N, S282F, A308T, N312S, L346P, P399L, S460F, D666G, S817T, P941S, C1135Y, R1167T, II 175V, S1204C, R1214W, D1242R, D1242V, Y1245S, R1261C, R1261H, R1261L, F1287L, W1291R, K1299E, K1299N, R1302G, E1318G, P1367S, C1396W, L1398R, V1417F, G1869W, L1872P, I1873T, C1875R, H1881Q, H1881R, R1896M, R1896S, S1898F, V1900A, G1913D, A1919V, R1926H, P1941S, P1962L
  • the human subject has clonal hematopoiesis of indeterminate potential (CHIP).
  • the human subject has at least one TET2 mutation with a variant allele fraction of at least 2%, 5%, 10%, 13.5%, 15%, 20%, 25%, 27%, 30%.
  • Identification of a TET2 mutation may be detected in a patient's genome, including an exome.
  • sequencing may comprise whole exome sequencing (WES).
  • the sequenced nucleic acid may include DNA.
  • DNMT3A mutations may cause or be associated with atherosclerosis.
  • One or more than one DNMT3A mutation may be present in a somatic blood cell clone.
  • a DNMT3A mutation may be a frameshift mutation, a nonsense mutation, a missense mutation, or a splice-site variant mutation.
  • a DNMT3A mutation may also be a loss-of-function DNMT3A mutation.
  • a mutation in DNMT3A leads to non-expression or decreased expression of the DNMT3A protein or expression of a truncated or non-functional form of the DNMT3A protein.
  • a mutation in DNMT3A leads to a change in the structure or function of the DNMT3A protein.
  • the Q9Y6K1-1 sequence is a representative wild-type amino acid sequence of DNMT3A.
  • the mutation in DNMT3A is a frameshift mutation.
  • the frameshift mutation is caused by insertion or deletion of a number of nucleotides that is not divisible by three.
  • the mutation in DNMT3A may also be an insertion or deletion of a number of nucleotides that is divisible by three, wherein one or more amino acids are added or deleted from the wild-type DNMT3A amino acid sequence.
  • the mutation in DNMT3A is a nonsense mutation.
  • the nonsense mutation is a point mutation (i.e., single nucleotide change) that results in a premature stop codon or a nonsense codon (i.e., a codon that does not code for an amino acid) in the transcribed RNA.
  • the nonsense mutation leads to a truncated, incomplete and/or nonfunctional DNMT3A protein.
  • the mutation in DNMT3A is a missense mutation.
  • the missense mutation is a point mutation that codes for a different amino acid than that found in the wildtype DNMT3A sequence.
  • the missense mutation is within nucleotides that encode one of the catalytic domains of the DNMT3A protein.
  • the missense mutation causes a change in amino acid from that encoded by the wildtype sequence at amino acids 634-914 of the DNMT3A protein.
  • the mutation in DNMT3A results in an amino acid change of 13 ION, Y365C, D529N, G532S, M548K, C549R, L648P, G699D, P700L, F732A, R749C, R771Q, V778G, N838D, R882C/H/P, F902S, P904L, or the absence of an amino acid corresponding to position 731.
  • the mutation in DNMT3A results in an amino acid change of F290I, F290C, V296M, P307S, P307R, R326H, R326L, R326C, R326S, G332R, G332E, V339A, V339M, V339G, L344Q, L344P, R366P, R366H, R366G, A368T, A368V, R379H, R379C, I407T, I407N, I407S, F414L, F414S, F414C, A462V, K468R, C497G, C497Y, Q527H, Q527P, Y533C, S535F, C537G, C537R, G543A, G543S, G543C, L547H, L547P, L547F, M548I, M548K,
  • IL-8 activity may be reduced using an IL-8 depleting drug or an IL-8 activity reducing drug.
  • the IL-8 inhibitor may comprise an anti-IL-8 antibody or antigen binding fragment thereof.
  • an anti-IL-8 antibody or antigen binding fragment thereof may comprise HuMaxIL-8, HuMab-10F8, or an antigen binding fragment thereof, but others may be employed as well.
  • Other IL-8 inhibitors include reparixin, 1 OZ-hy menial disine, azelastine, celastrol, TNFRSF1A protein, TNFSF10 protein, TNFRSF10B protein, Ac-RRWWCR-Nifc hexapepiide, and cufcumm.
  • An IL-8 inhibitor may, in some instances, interfere with IL-8 binding or activity at its receptor, CXCR2, or the level or activity of CXCR2 itself.
  • an IL-8 inhibitor may comprise an inhibitor of CXCR2. These include, but are not limited to, an anti-CXCR2 antibody or antigen binding fragment thereof.
  • An IL-8 inhibitor may also comprise the CXCR2 inhibitor SB-332235 (GlaxoSmithKline) or the CXCR2 antagonist AZD5069.
  • IL-6 activity may be reduced using an IL-6 depleting drug or an IL-6 activity reducing drug.
  • the IL-6 inhibitor may comprise an IL-6 antibody or antigen binding fragment thereof.
  • an IL-6 antibody or antigen binding fragment thereof may comprise siltuximab, olokizumab, elsilimomab, mAb 1339, BMS-945429 (also known as ALD518), sirukumab, CPSI-2364, ALX- 0061, clazakizumab, ARGX-109, MEDI5117, FE301, FM101, or C326.
  • An IL-6 inhibitor may, in certain embodiments, interfere with IL-6 binding or activity at its receptor, IL-6R, or the level of activity of IL-6R itself. It may also interfere with binding or activity to gpl30. As a transmembrane signal transduction protein, gpl30 associates with the complex of IL-6 and IL-6R to produce downstream signals. Thus, an IL-6 inhibitor may comprise an inhibitor of IL-6R and/or gpl30. These include, but are not limited to tocilizumab or sarilumab.
  • IL-6 inhibitors are disclosed in US20120294852 and include tamibarotene, all-trans retinoic acid (ATRA).
  • ATRA all-trans retinoic acid
  • Low-dose methotrexate has also been shown to improve IL-6 levels in patients with rheumatoid arthritis and may be useful for treatment of atherosclerosis, as is being tested in the CIRT study.
  • Low-dose methotrexate may include doses of from 15 to 20 mg/week.
  • IL- ⁇ activity may be reduced using an IL- ⁇ depleting drug or an IL- ⁇ ⁇ activity reducing drug.
  • the IL- ⁇ ⁇ inhibitor may comprise an IL- ⁇ ⁇ antibody or antigen binding fragment thereof.
  • an IL- ⁇ ⁇ antibody or antigen binding fragment thereof may comprise canakinumab.
  • An IL-1 receptor antagonist, such as anakinra, can also serve as an IL- ⁇ ⁇ inhibitor.
  • IL- ⁇ ⁇ inhibitor is an inhibitor of the IL- ⁇ ⁇ receptor.
  • an anti- IL- ⁇ antibody or antigen binding fragment thereof may be used.
  • Low-dose methotrexate (for example from 15 to 20 mg/week) has also been shown to improve IL- ⁇ ⁇ levels in patients with rheumatoid arthritis and may be useful for treatment of atherosclerosis, as is being tested in the CIRT study.
  • a subject or patient benefitting herein may have one or more of the following patient profile characteristics.
  • the human subject may also exhibit one or more risk factors of being a smoker, having level of total cholesterol of at least 200 mg/dL, or having level of low-density lipoprotein (LDL) of at least 130 mg/dL.
  • LDL low-density lipoprotein
  • the human subject has a total cholesterol of at least 240 mg/dL and/or an LDL of at least 160 mg/dL.
  • the human subject has elevated hsCRP and optionally an hsCRP level of at least 2 mg/L.
  • the method may include (i) administering an effective amount of cholesterol-lowering medication and/or (ii) prescribing exercise, cessation of smoking, diet modification, and/or stress reduction to the subject.
  • cholesterol-lowering medication for combination therapy may include, but is not limited to, comprises at least one PCSK9 inhibitor, at least one statin, at least one selective cholesterol absorption inhibitor, at least one resin, at least one lipid-lowering therapy, at least one CETP inhibitor, at least one pantothenic acid derivative, at least one microsomal triglyceride transfer protein (MTP) inhibitor, at least one adenosine triphosphate-binding cassette transporter A 1 (ABCAl)-promoter, aspirin, estrogen, and/or at least one lipoprotein complex.
  • PCSK9 inhibitor comprises at least one PCSK9 inhibitor, at least one statin, at least one selective cholesterol absorption inhibitor, at least one resin, at least one lipid-lowering therapy, at least one CETP inhibitor, at least one pantothenic acid derivative, at least one microsomal triglyceride transfer protein (MTP) inhibitor, at least one adenosine triphosphate-binding cassette transporter A 1 (ABCAl)-promoter, aspirin, estrogen
  • PCSK9 inhibitors may be used, including but not limited to a PCSK9 antibody or antigen binding fragment thereof.
  • specific PCSK9 antibodies as well as antigen binding fragments of those antibodies, disclosed in US 2015/0140002A1 are incorporated by reference herein.
  • Specific PCSK9 antibodies include evolocumab, alirocumab, bococizumab, LGT209, RG7652, or LY3015014.
  • PCSK9 inhibitors also include RNAi therapeutic agents that inhibit the synthesis of PCSK9, such as inclisiran.
  • PCSK9 inhibitors also include an antisense RNA that inhibits the synthesis of PCSK9, such as ISIS-405879/BMS-844421.
  • PCSK9 inhibitors also include a PCSK9-targeting vaccine, such as AT04A or AT06A.
  • PCSK9 inhibitors further include a polypeptide that binds PCSK9 (such as adnectin) or a locked nucleic acid targeting PCSK9 (such as SPC5001).
  • Statins also known as HMG CoA reductase inhibitors
  • Statins also known as HMG CoA reductase inhibitors, are also included in the class of cholesterol-lowering medication. This class of drugs works in the liver to prevent the formation of cholesterol, thus lowering the amount of cholesterol circulating in the blood. Statins are most effective at lowering LDL cholesterol, but also have modest effects on lowering triglycerides and raising HDL cholesterol.
  • Exemplary statins include, but are not limited to, atorvastatin (Lipitor ® ), fluvastatin (Lescol ® ), lovastatin (Mevacor ® , AltoprevTM), pravastatin (Pravachol ® ), rosuvastatin (rosuvastatin calcium, Crestor ® ), simvastatin (Zocor ® ), and pitavastatin.
  • Statins are also found in the combination medications Advicor ® (lovastatin + niacin), Caduet ® (atorvastatin + amlodipine), and VytorinTM (simvastatin + ezetimibe).
  • Selective cholesterol absorption inhibitors may also be used as cholesterol- lowering medication. This relatively new class of cholesterol-lowering medications works by preventing the absorption of cholesterol from the intestine. Selective cholesterol absorption inhibitors are most effective at lowering LDL cholesterol, but may also have modest effects on lowering triglycerides and raising HDL cholesterol.
  • An example of a selective cholesterol absorption inhibitor includes ezetimibe (Zetia ® ). 4. Resins
  • Cholesterol-lowering medication also includes resins (i.e., bile acid sequesterant or bile acid-binding drugs or bile-acid resin).
  • resins i.e., bile acid sequesterant or bile acid-binding drugs or bile-acid resin.
  • This class of LDL-lowering drugs works in the intestines by promoting increased disposal of cholesterol.
  • the medications bind to bile, which then cannot be used in digestion, and the patient's body responds by making more bile and using stores of cholesterol.
  • Resins may include, but are not limited to, cholestyramine (Questran ® , Questran ® Light, Prevalite ® , Locholest ® , Locholest ® Light), Colestipol (Colestid ® ), and
  • Cholesterol-lowering medication further includes lipid-lowering therapies, such as at least one fibrate, niacin, and at least one omega-3 fatty acid.
  • Fibrates are best at lowering triglycerides and in some cases increasing HDL levels, but are not as effective in lowering LDL cholesterol.
  • Fibrates include gemfibrozil (Lopid®), fenofibrate (Antara®, Lofibra®, Tricor®, and TriglideTM), and clofibrate (Atromid-S).
  • Niacin (nicotinic acid) functions in the liver by affecting the production of blood fats.
  • Omega-3 fatty acids help decrease triglyceride secretion and facilitate triglyceride clearance.
  • Omega-3 fatty acids include omega-3 fatty acid ethyl esters are derived from fish oils that may be chemically changed and purified.
  • Omega-3 fatty acid ethyl esters available in the U.S. include Lovaza® (omega-3-acid ethyl esters) and VascepaTM (icosapent ethyl).
  • Omega-3 fatty acids also include omega-3 polyunsaturated fatty acids, including but not limited to marine- derived omega-3 polyunsaturated fatty acids (PUFA).
  • PUFA marine- derived omega-3 polyunsaturated fatty acids
  • Cholesterol-lowering medications include at least one CETP inhibitor.
  • These medications inhibit cholesterylester transfer protein (CETP) and are intended to improve blood lipid levels by increasing HDL, lowering LDL, and by reversing the transport of cholesterol.
  • CETP cholesterylester transfer protein
  • These medications include anacetrapib and obicetrapib.
  • MTP Microsomal Triglyceride Transfer Protein
  • Cholesterol-lowering medications also include microsomal triglyceride transfer protein (MTP) inhibitors, which inhibit very-low-density lipoprotein production in the liver and chylomicron inhibition in the intestine.
  • MTP microsomal triglyceride transfer protein
  • the MTP inhibitor is chosen from at least one of (i) a small molecule that inhibits function of MTP, (ii) an RNAi therapeutic agent that inhibits the synthesis of MTP, and (iii) an antisense RNA that inhibits synthesis of
  • MTP MTP
  • the small molecule that inhibits function of MTP may be chosen from at least one of lomitapide, JTT-130, Slx-4090, and dirlotapide.
  • ABCA1 Adenosine Triphosphate-Binding Cassette Transporter Al
  • Cholesterol-lowering medications further include at least one adenosine triphosphate-binding cassette transporter Al (ABCAl)-promoter. These may be chosen from at least one of (i) an apoA-1 mimetic peptide, (ii) a full-length apoA-1, and (iii) a reconstituted HDL.
  • the apoA-1 mimetic peptide may be FAMP type 5 (FAMP5).
  • the full-length apoA-1 may be ApoA-l-Milano or ETC-216.
  • Other cholesterol lowering medications at least one lipoprotein complex.
  • a lipoprotein complex may be CER-001, CSL-111, CSL-112, and ETC-216.
  • a lipoprotein complex may be chosen from at least one of apolipoprotein or apolipoprotein peptide mimic.
  • apolipoprotein is chosen from at least one of ApoA-I, ApoA-II, ApoA-IV, and ApoE and/or
  • the peptide mimetic is chosen from at least one of ApoA-I, ApoA-II, ApoA-IV, and ApoE peptide mimic.
  • lifestyle modification may be prescribed to the subject.
  • Exercise may be prescribed to the subject, for example for at least 3, 4, 5, 6, or 7 days a week.
  • Exercise may include cardiovascular conditioning exercise and/or strength training exercise.
  • the subject performs the prescribed exercise as directed.
  • the method may also include prescribing cessation of smoking and/or the subject stopping smoking or reducing smoking levels.
  • the method may also comprise administering a medication to support smoking cessation (including medication chosen from at least one of nicotine replacement therapy, antidepressants (such as bupropion, nortriptyline, or an SSRI), varenicline, and clonidine).
  • a medication to support smoking cessation including medication chosen from at least one of nicotine replacement therapy, antidepressants (such as bupropion, nortriptyline, or an SSRI), varenicline, and clonidine).
  • the method may also comprise a prescription for diet modification and/or the subject modifying his or her diet.
  • Diet modification may include at least one of a reduction in fat consumption, a reduction in cholesterol consumption, a reduction in sugar consumption, an increase in fruit and/or vegetable consumption, an increase in omega fatty acids, and/or reduction of alcohol consumption.
  • Weight loss may be accomplished through a variety of factors including medications to promote weight loss, including celastrol.
  • the method may also include prescription of stress reduction and/or the subject reducing his or her stress levels, including but not limited to at least one of relaxation techniques, mediation, breathing exercises, exercise, and/or anger management. Stress reduction includes managing constant levels of stress more effectively.
  • the method may also include prescribing psychiatric medication and/or the subject taking psychiatric medication, such as but not limited to anti-anxiety medication and/or anti-depressant medication.
  • psychiatric medication such as but not limited to anti-anxiety medication and/or anti-depressant medication.
  • Such medications may include at least one of citalopram, escitalopram, fluoxetine, paroxetine, sertraline, duloxetine, venlafaxine, imipramine, hydroxyzine, propanolol, gabapentin, and pregabalin.
  • the method may also comprise prescribing or conducting psychological counseling.
  • a method for diagnosing atherosclerosis in a human subject comprises determining whether the subject has an increased level of IL-8, IL-6, and/or IL- ⁇ ; and diagnosing the subject as having atherosclerosis when an increased level of IL-8, IL-6, and/or IL- ⁇ is present.
  • the increased level of IL-8 is an increased level of plasma IL-8.
  • the increased level of plasma IL-8 may be at least about 20 ng/mL. Or it may be at least about 25, 30, 40, 45, 50, 55, 60, 65, 70, 75, or 80 ng/mL.
  • the increased level of IL-8, IL-6, and/or IL- ⁇ ⁇ may be an increased level of IL-8, IL- 6, and/or IL- ⁇ ⁇ RNA. In some situations, the increased level of IL-8, IL-6, and/or IL- ⁇ ⁇ may be an increased level of IL-8, IL-6, and/or IL- ⁇ in cells. The increased levels of IL-8, IL-6, and/or IL- ⁇ may be about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% increased over baseline levels for normal subjects.
  • the method includes both evaluating IL-8, IL-6, and/or IL- ⁇ ⁇ levels and determining whether the subject has a TET2 and/or DNMT3A mutation.
  • Such additional steps could comprise detecting whether the sample contains at least one TET2 and/or DNMT3A mutation with a probe of sufficient length and composition to detect a TET2 and/or DNMT3A mutation; and diagnosing the subject as having atherosclerosis when at least one TET2 and/or DNMT3A mutation is detected.
  • a method of detecting at least one TET2 and/or DNMT3A mutation along with an increase in plasma level of IL-8, IL-6, and/or IL- ⁇ ⁇ in a human subject comprises: (a) obtaining a nucleic acid sample from the subject; (b) detecting whether the sample contains at least one TET2 and/or DNMT3A mutation with a probe of sufficient length and composition to detect a TET2 and/or DNMT3A mutation; (c) obtaining a plasma sample from the subject; and (d) determining whether the subject has an increased level of IL-8, IL-6, and/or IL- ⁇ , as further described in paragraph [00109] above.
  • Atherosclerosis means any form of hardening and/or narrowing of the arteries. This includes any amount of plaque build-up in the artery wall. Plaque is made up of cholesterol, fatty substances, cellular waste products, calcium, and fibrin. Atherosclerosis includes formation of early plaques before diagnosis would usually occur. Plaques have been shown to form in much younger adults than those individuals generally diagnosed with atherosclerosis.
  • Loss-of-function mutation means any inactivating mutation resulting in the gene product having less or no function (partially or wholly inactivated). A loss-of-function mutation may result in the mutant form having no activity or 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or higher percentage reduction in activity.
  • the term "about” means a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated.
  • the term “about” refers generally to a range of numerical values (e.g., +/- 5 to 10% of the recited range) that one of ordinary skill in the art would consider equivalent to the recited range (e.g., having the same function or result).
  • the terms modify all of the values or ranges provided in the list.
  • the term about may include numerical values that are rounded to the nearest significant figure.
  • an antibody is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
  • an antibody may be a chimeric antibody, a humanized antibody, or a human antibody.
  • antibody includes, but is not limited to, fragments that are capable of binding to an antigen, such as Fv, single-chain Fv (scFv), Fab, Fab', di-scFv, sdAb (single domain antibody) and (Fab')2 (including a chemically linked F(ab')2).
  • the term antibody also includes, but is not limited to, chimeric antibodies, humanized antibodies, and antibodies of various species such as mouse, human, cynomolgus monkey, etc.
  • Antibody fragments also include either orientation of single chain scFvs, tandem di-scFv, diabodies, tandem tri-sdcFv, minibodies, etc.
  • Antibody fragments also include nanobodies (sdAb, an antibody having a single, monomelic domain, such as a pair of variable domains of heavy chains, without a light chain).
  • An antibody fragment can be referred to as being a specific species in some
  • antisense oligonucleotide refers to a single-stranded oligonucleotide comprising 8 to 50 monomeric units and having a nucleobase sequence that permits hybridization to a corresponding segment of a target nucleic acid.
  • An antisense oligonucleotide may comprise natural, non-natural, and/or modified nucleosides and/or intemucleoside linkages.
  • peptide refers to a molecule formed by linking at least two, and up to 300, amino acids by amide bonds.
  • the amino acids of a peptide may be natural, non-natural, and/or modified amino acids.
  • a peptide comprises 2- 200 amino acids, or 2-100 amino acids, or 2-50 amino acids, or 2-30 amino acids, or 10-300 amino acids, or 10-200 amino acids, or 10-100 amino acids, or 10-50 amino acids.
  • a “reference” as used herein refers to any sample, standard, or level that is used for comparison purposes.
  • a reference may be obtained from a healthy and/or non- diseased sample.
  • a reference may be obtained from an untreated sample, or may be a sample from the subject prior to treatment.
  • a reference is obtained from one or more healthy individuals who are not the subject or patient.
  • diagnosis or "identifying a patient having” refers to a process of determining if an individual is afflicted with, or has a genetic predisposition to develop, atherosclerosis.
  • a "companion diagnostic” refers to a diagnostic method and or reagent that is used to identify subjects susceptible to treatment with a particular treatment or to monitor treatment and/or to identify an effective dosage for a subject or subgroup or other group of subjects.
  • a companion diagnostic refers to reagents, such as DNA isolation and sequencing reagents, that are used to detect somatic mutations in a sample.
  • the companion diagnostic refers to the reagents and also to the test(s) that is/are performed with the reagent.
  • treat refers to reducing or ameliorating atherosclerosis or symptoms associated therewith. It will be appreciated that, although not precluded, treating atherosclerosis or the risk of developing atherosclerosis does not require that the disease or the risk be completely eliminated.
  • a "treatment” is a procedure which alleviates or reduces the negative consequences of atherosclerosis. Any treatments or potential treatments can be used in the context herein.
  • a treatment is not necessarily curative, and may reduce the effect of atherosclerosis by a certain percentage over an untreated subject. The percentage reduction or diminution can be from 10% up to 20, 30, 40, 50, 60, 70, 80, 90, 95, 99 or 100%.
  • Treatment also includes methods or preventing, inhibiting the development, or reducing the risk of atherosclerosis, unless otherwise stated.
  • Methods of treatment may be personalized medicine procedures, in which the DNA of an individual is analyzed to provide guidance on the appropriate therapy for that specific individual.
  • the methods may provide guidance as to whether treatment is necessary, as well as revealing progress of the treatment and guiding the requirement for further treatment of the individual.
  • Atherosclerosis in a patient who may not have atherosclerosis, but may have a genetic predisposition to developing atherosclerosis.
  • at risk refers to having a propensity to develop atherosclerosis.
  • a patient having a genetic mutation in a gene associated with atherosclerosis has increased risk (e.g., "higher predisposition") of developing the disease relative to a control subject having a "lower predisposition” (e.g., a patient without a TET2 mutation and/or increased IL-8 levels).
  • reduces may mean a negative alteration of at least 10%, 15%, 25%, 50%, 75%, or 100%.
  • a "therapeutically effective amount” refers to the amount of a compound required to improve, inhibit, or ameliorate a condition of a patient, or a symptom of a disease, in a clinically relevant manner. Any improvement in the patient is considered sufficient to achieve treatment.
  • a sufficient amount of an active compound used for the treatment of atherosclerosis varies depending upon the manner of administration, the age, body weight, genotype, and general health of the patient. Ultimately, the prescribers or researchers will decide the appropriate amount and dosage regimen. Such determinations are routine to one of ordinary skill in the art.
  • patient or “subject” refers to any human being receiving or who may receive medical treatment. These terms also include mammals. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats).
  • a "somatic mutation” refers to a change in the genetic structure that is not inherited from a parent, and also not passed to offspring.
  • Administration of medicaments may be by any suitable means that results in a compound concentration that is effective for treating or inhibiting (e.g., by delaying) the development of atherosclerosis.
  • the compound is admixed with a suitable carrier substance, e.g., a pharmaceutically acceptable excipient that preserves the therapeutic properties of the compound with which it is administered.
  • a suitable carrier substance e.g., a pharmaceutically acceptable excipient that preserves the therapeutic properties of the compound with which it is administered.
  • One exemplary pharmaceutically acceptable excipient is physiological saline.
  • the suitable carrier substance is generally present in an amount of 1-95% by weight of the total weight of the medicament.
  • the medicament may be provided in a dosage form that is suitable for oral, rectal, intravenous, intramuscular, subcutaneous, inhalation, nasal, topical or transdermal, vaginal, or ophthalmic administration.
  • the medicament may be in form of, e.g., tablets, capsules, pills, powders, granulates, suspensions, emulsions, solutions, gels including hydrogels, pastes, ointments, creams, plasters, drenches, delivery devices, suppositories, enemas, injectables, implants, sprays, or aerosols.
  • genomic DNA may be obtained from a sample of tissue or cells taken from that patient.
  • the tissue sample may comprise but is not limited to hair (including roots), skin, buccal swabs, blood, saliva, or plasma, including but not limited to cell-free DNA from plasma.
  • the tissue sample may be marked with an identifying number or other indicia that relates the sample to the individual patient from which the sample was taken.
  • the identity of the sample advantageously remains constant throughout, thereby guaranteeing the integrity and continuity of the sample during extraction and analysis.
  • the indicia may be changed in a regular fashion that ensures that the data, and any other associated data, can be related back to the patient from whom the data was obtained.
  • the amount size of sample required is known to those skilled in the art.
  • the tissue sample may be placed in a container that is labeled using a numbering system bearing a code corresponding to the patient. Accordingly, the genotype of a particular patient is easily traceable.
  • a sampling device and/or container may be supplied to the physician.
  • the sampling device advantageously takes a consistent and reproducible sample from individual patients while simultaneously avoiding any cross-contamination of tissue. Accordingly, the size and volume of sample tissues derived from individual patients would be consistent.
  • a sample of DNA may be obtained from the tissue sample of the patient of interest. Whatever source of cells or tissue is used, a sufficient amount of cells must be obtained to provide a sufficient amount of DNA for analysis. This amount will be known or readily determinable by those skilled in the art.
  • DNA may be isolated from the tissue/cells by techniques known to those skilled in the art (see, e.g., U.S. Pat. Nos. 6,548,256 and 5,989,431, Hirota et al, Jinrui Idengaku Zasshi. September 1989; 34(3):217-23 and John et al, Nucleic Acids Res. Jan. 25. 1991;
  • high molecular weight DNA may be purified from cells or tissue using proteinase K extraction and ethanol precipitation. DNA may be extracted from a patient specimen using any other suitable methods known in the art.
  • genotype There are many methods known in the art for determining the genotype of a patient and for identifying or analyzing whether a given DNA sample contains a particular somatic mutation. Any method for determining genotype can be used. Such methods include, but are not limited to, amplimer sequencing, DNA sequencing, fluorescence spectroscopy, fluorescence resonance energy transfer (or "FRET")-based hybridization analysis, high throughput screening, mass spectroscopy, nucleic acid hybridization, polymerase chain reaction (PCR), RFLP analysis and size chromatography (e.g., capillary or gel chromatography), all of which are well known to one of skill in the art.
  • FRET fluorescence resonance energy transfer
  • test kit may comprise any of the materials necessary for whole exome sequencing and targeted amplicon sequencing, for example.
  • a companion diagnostic may comprise testing for TET2 and/or DNMT3A mutations.
  • the kit further comprises additional means, such as reagents, for detecting or measuring TET2 and/or DNMT3A sequences, and also ideally a positive and negative control.
  • the methods further encompass probes that are immobilized on a solid or flexible support, such as paper, nylon or other type of membrane, filter, chip, glass slide, microchips, microbeads, or any other such matrix, all of which are within the scope of this application.
  • a solid or flexible support such as paper, nylon or other type of membrane, filter, chip, glass slide, microchips, microbeads, or any other such matrix, all of which are within the scope of this application.
  • the probe of this form is now called a "DNA chip”. These DNA chips can be used for analyzing the somatic mutations.
  • Arrays or microarrays of nucleic acid molecules that are based on one or more of the sequences described herein are included.
  • arrays or “microarrays” refers to an array of distinct polynucleotides or oligonucleotides synthesized on a solid or flexible support, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support.
  • the microarray is prepared and used according to the methods and devices described in U.S. Pat. Nos. 5,446,603; 5,545,531 ;
  • Sequence identity or homology may be determined by comparing the sequences when aligned so as to maximize overlap and identity while minimizing sequence gaps.
  • sequence identity may be determined using any of a number of mathematical algorithms.
  • a nonlimiting example of a mathematical algorithm used for comparison of two sequences is the algorithm of Karlin & Altschul, Proc. Natl. Acad. Sci. USA 1990;87: 2264- 2268, modified as in Karlin & Altschul, Proc. Natl. Acad. Sci. USA 1993;90: 5873-5877.
  • Another example of a mathematical algorithm used for comparison of sequences is the algorithm of Myers & Miller, CABIOS 1988;4: 11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Yet another useful algorithm for identifying regions of local sequence similarity and alignment is the FASTA algorithm as described in Pearson & Lipman, Proc. Natl. Acad. Sci. USA 1988;85: 2444-2448.
  • WU-BLAST Wood University BLAST
  • WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from the FTP site for Blast at the Washington University in St. Louis website. This program is based on WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul & Gish, 1996, Local alignment statistics, Doolittle ed., Methods in Enzymology 266: 460-480; Altschul et al., Journal of Molecular Biology 1990; 215: 403-410; Gish & States, 1993; Nature Genetics 3: 266-272; Karlin & Altschul, 1993; Proc. Natl. Acad. Sci. USA 90: 5873-5877; all of which are incorporated by reference herein).
  • the gapped alignment routines are integral to the database search itself. Gapping can be turned off if desired.
  • the default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.
  • the term "homology” or "identity”, for instance, with respect to a nucleotide or amino acid sequence, can indicate a quantitative measure of homology between two sequences.
  • the percent sequence homology can be calculated as (Nref-Ndif)* 100/- N re f, wherein N ⁇ uf is the total number of non-identical residues in the two sequences when aligned and wherein Nref is the number of residues in one of the sequences.
  • “Homology” or “identity” can refer to the number of positions with identical nucleotides or amino acids divided by the number of nucleotides or amino acids in the shorter of the two sequences wherein alignment of the two sequences can be determined in accordance with the Wilbur and Lipman algorithm (Wilbur & Lipman, Proc Natl Acad Sci USA 1983;80:726, incorporated herein by reference), for instance, using a window size of 20 nucleotides, a word length of 4 nucleotides, and a gap penalty of 4, and computer-assisted analysis and interpretation of the sequence data including alignment can be conveniently performed using commercially available programs (e.g., Intelligenetics. TM. Suite, Intelligenetics Inc. CA).
  • RNA sequences are said to be similar, or have a degree of sequence identity or homology with DNA sequences, thymidine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence.
  • RNA sequences are within the scope of the application and can be derived from DNA sequences, by thymidine (T) in the DNA sequence being considered equal to uracil (U) in RNA sequences.
  • Another aspect includes a method of screening patients to determine those patients more likely to develop atherosclerosis comprising the steps of obtaining a sample of genetic material from a patient; and assaying for the presence of a genotype in the patient which is associated with developing atherosclerosis, any of the herein disclosed somatic mutations.
  • the step of assaying is chosen from: restriction fragment length polymorphism (RFLP) analysis, minisequencing, MALD-TOF, SINE, heteroduplex analysis, single strand conformational polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE) and temperature gradient gel electrophoresis (TGGE).
  • RFLP restriction fragment length polymorphism
  • MALD-TOF massive laser deposition
  • SINE single strand conformational polymorphism
  • SSCP single strand conformational polymorphism
  • DGGE denaturing gradient gel electrophoresis
  • TGGE temperature gradient gel electrophoresis
  • the MDC study is a community-based, prospective observational study of
  • the Biolmage study (NCT00738725) is a multi-ethnic, observational study aimed at characterizing subclinical atherosclerosis in 6,699 US adults (55-80 years at baseline, 2008-2009) at risk for, but without, clinical cardiovascular disease. From this cohort, those of European ancestry who sustained incident major adverse cardiovascular disease events, including fatal or non-fatal myocardial infarction, coronary artery bypass grafting, or percutaneous coronary were selected intervention for whole exome sequencing (see Baber U et al., J Am Coll Cardiol 65: 1065-74 (2015)). DNA was obtained from whole blood samples at the time of study enrollment and individuals were followed for the development of coronary heart disease.
  • the Atherosclerosis, Thrombosis, and Vascular Biology (ATVB) Study is a nationwide case-control study of early-onset myocardial infarction involving 125 Italian coronary care units ⁇ see ATVB Italian Study Group 2003). Cases were men and women hospitalized for a first myocardial infarction before the age of 45 years who underwent coronary angiography at the time of index hospitalization. Acute myocardial infarction was defined as resting chest pain lasting >30 minutes accompanied by ST-segment elevation evolving into pathological Q waves with total creatinine kinase or MB fraction levels of >2X the upper normal limit of normal.
  • JHS The Jackson Heart Study
  • FHS Framingham Heart Study
  • Samples in these two analyses were initially selected for exome sequencing as cases or controls for studies of myocardial infarction, blood pressure, LDL cholesterol, stroke, atrial fibrillation as well as randomly selected.
  • FHS exomes on dbGaP derived from peripheral blood samples were utilized.
  • Exomes derived from lymphoblast cell lines were excluded. DNA was obtained from whole blood samples at the time of study enrollment and individuals were followed for the development of coronary heart disease.
  • Table 1 shows the baseline characteristics for each cohort. After excluding those with prevalent events, cases were defined as those having myocardial infarction or coronary revascularization procedures incident to the time of DNA collection and were matched to event-free controls by age (+/- 2 years), sex, type 2 diabetes status, and smoking history.
  • Hypertension defined as systolic blood pressure > 140 mm Hg or use of hypertensive medications.
  • T2D type 2 diabetes.
  • HDL-C high density lipoprotein cholesterol [00164] The association between clonal hematopoiesis (CHIP) and coronary heart disease was analyzed based on previous exploratory results (see Jaiswal 2014) by utilizing a nested case-control study design.
  • Table 2 List of hemato oietic enes and variants ueried
  • Frameshift, nonsense, and splice-site mutations were further excluded if they occurred in the first or last 10% of the gene open reading frame, unless mutations in those regions had been previously reported, (e.g. DNMT3A).
  • Frameshift mutations were also excluded if the insertions/deletions occurred in homo-polymer repeats (5 consecutive reads of the same nucleotide) unless there were a total 10 or more supporting reads and a VAF>8% for these indels.
  • VAF variant allele frequency
  • a Cox proportional hazards model with mutated gene as a factor with 6 levels did not interfere with case-control matching.
  • a Cox proportional hazards model with mutated gene as a factor with 6 levels (DNMT3A mutation, TET2 mutation, ASXL 1 mutation, JAK2 mutation, other mutation, or no mutation), in addition to age (categorical variable, ⁇ 50 years, 50-59 years, 60-69 years, > 70 years), sex, type 2 diabetes status, total cholesterol, high density lipoprotein cholesterol, smoking status (current or former smoker versus never smoker), and hypertension (systolic blood pressure >160 mm Hg) as covariables was used.
  • Coronary artery calcification (CAC) scores were obtained from participants at the time of study enrollment as previously described (Muntendam P, et al, Am Heart J 160:49057 el (2010)). To test for associations between CHIP and coronary artery calcification, computed tomography generated coronary artery calcification scores were log- transformed in Agatston units (natural logarithm (coronary artery calcification score +1)) and used linear regression with presence of CHIP, age (continuous variable), sex, type 2 diabetes status, total cholesterol (continuous variable), high density lipoprotein cholesterol (continuous variable), hypertension (categorical variable), and smoking status (current or former smoker versus never smoker) as co-variables. In a separate analysis, CHIP was used with a mutation variant allele fraction below or greater than or equal to the median (13.5%) as a variable, in addition to the other co-variables listed above, in a linear regression model.
  • mice with loss-of-function of Tet2 in all hematopoietic cells were evaluated.
  • Tet2 tml Uaai /J (Jax Cat. No. 017573) (see Moran-Crusio K et al, Cancer Cell 20: 11-24 (2011)) and the hypercholesterolemia-prone Ldlr knockout (KO) line B6; 129S7-Ldlr tmme VJ (Jax Cat. No. 002207).
  • Ldlr KO mice were crossed with B6.SJL-Ptprc a Pepc h /BoyJ (Jax Cat. No. 002014) to generate Ldlr KO mice homozygous for the panleukocyte marker CD45.1.
  • female Ldlr KO mice were used exclusively as recipients.
  • TTCTTTAGCCCTTGCTGAGC (Flox R; SEQ ID NO: 3). This assay distinguishes between the wild-type allele (248 bp), the floxed allele (480 bp), and the excised allele (580 bp).
  • recipient Ldlr KO CD45.1 + mice were lethally irradiated with two doses of ⁇ -irradiation (475 cGy) separated by 4 hours.
  • Donor CD45.2 + bone marrow was obtained from Tet2 +/+, Tet2 +/flox, or Tet2 flox/flox littermates.
  • Post-irradiation recipients were transplanted with 2x l0 6 whole bone marrow cells in suspension via retro-orbital injection. Following transplantation, recipient mice were provided with sterilized cages, food, and water for a period of four weeks. Water was supplemented with antibiotic (trimethoprim-sulfamethoxazole) for the first three weeks after transplant.
  • antibiotic trimethoprim-sulfamethoxazole
  • mice were started on high fat, high cholesterol diet at four-weeks post-transplant (Harlan-Teklad, TD.96121 ; 21% MF, 1.25% Choi. Diet). This hypercholesterolemia-promoting regimen was continued for 5, 9, 13, or 17 weeks.
  • mice Immediately prior to euthanization, peripheral blood samples from overnight-fasted mice were obtained by terminal bleeding via the retro-orbital sinus. Serum was isolated from EDTA-free blood and frozen at -80°C until characterization for lipids or proteins. For serum lipid measurements, total cholesterol (Wako, Cat. No. 439-17501), high density lipoprotein cholesterol (Wako, Cat. No. 431-52501), and triglycerides (Cayman Chemical, Cat. No. 10010303) were measured in serum from mice at 17 weeks on diet after overnight fasting.
  • Trichrome 2000 stain (American MasterTech, Cat. No. KTMTR2) to evaluate sclerosis and fibrosis. Images of roots were acquired using a Nikon Eclipse E400 microscope. Quantification of aortic root lesions was performed using ImageJ (www.rsb.info.nih.gov/ij/index.html) on 5 or 6 adjacent, ORO-stained cryostat sections. The total lesion area on each slide was then averaged to obtain a mean lesion area per mouse.
  • cryostat sections were fixed in acetone at
  • Aortas were cut ⁇ 5mm inferior to the branchpoint of the subclavian artery and then fixed in 10% formalin overnight, cleaned of visceral fat deposits, opened
  • Rat anti-Mac2 1 : 100 (cat No.CL8942AP, Cedarlane labs, Burlington, Canada) was used on paraffin sections after pre-treatment of tissue sections with hit retrieval solution (Cat No. SI 699, Dako).
  • Color Deconvolution module in ImageJ2 (Fiji release) in H DAB mode.
  • a threshold was applied to Color 1 (hematoxylin) and Color 2 (3,3'-diaminobenzidine) to convert to black and white pixels.
  • the total number of pixels in Color 2 was divided by total number of pixels in Color 1 to give a percent area that stained positive for IHC.
  • Tet2 was selected because it is the second most commonly mutated gene in CHIP and significantly associated with higher risk of coronary heart disease in two sets of human cohorts in a previous study ( Figure 3B and 3C). Previous studies have demonstrated that hematopoietic stem cells from these mice recapitulate the clonal advantage of TET2 mutant hematopoietic cells seen in humans (see Moran-Crusio 2011).
  • mice that received Tet2-I- bone marrow had larger atherosclerotic lesions at all time points tested compared to mice that received control bone marrow.
  • Example 7 Loss of Tet2 function in myeloid cells enhances atherosclerosis in mice and alters macrophage inflammatory gene expression in vitro and in vivo
  • Tet2 catalyzes DNA hydroxymethylation (see Tahiliani M et al, Science 324:930-5 (2009)), an epigenetic modification that can influence gene transcription. Therefore, Tet2 may modulate gene expression in macrophages in response to environmental stimuli such as excess cholesterol or bacterial endotoxin.
  • BMDM Bone marrow-derived macrophages
  • IMDM Iscove's Modification of DMEM
  • FBS fetal bovine serum
  • MCSF mouse macrophage colony stimulating factor
  • PSG penicillin/streptomycin/glutamine
  • PSG penicillin/streptomycin/glutamine
  • IMDM IMDM with 10% FBS, 1% PSG, and 10 ng/mL M-CSF. After 24 hours, the media was replaced with media containing LDL, LPS, or vehicle as described below.
  • Native human low-density lipoprotein LDL, Alfa Aeser, Cat No.
  • BT-903 was resuspended to a final concentration of 200 mg/dL, along with 10% FBS, 1% PSG, and 10 ng/mL recombinant mouse M-CSF into IX IMDM from powdered stock (Life Technologies, Cat. No. 12200036).
  • LDL was replaced with 0.05M TRIS-HCl buffer, with 0.15M NaCl and 0.3mM EDTA, pH 7.4 in the above mixture.
  • Escherichia coli was also used in some experiments at a final concentration of 10 ng/mL in IX IMDM with 10% FBS, 1% PSG, and 10 ng/mL M-CSF.
  • LPS was replaced with phosphate buffered saline (Gibco).
  • BMDM were treated with LDL or vehicle as described above and harvested after 24h using Trizol reagent (Invitrogen, Cat. No. 15596026). RNA was purified using RNeasy Mini columns (Qiagen, Cat. No. 74104) followed by DNase treatment (TURBO DNA-free Kit, Life Technologies, Cat. No. AM 1907).
  • Ribo-Zero Kit (Illumina, Cat. No. MRZH116) was used to eliminate ribosomal RNA.
  • Library preparation using poly -A selection, multiplexing, and sequencing on two HiSeq2500 lanes were done by Genewiz (South Plainfield, NJ). A total of 10 samples were sequenced (3 Tet2+/+ untreated, 3 Tet2-/- untreated, 2 Tet2+/+ LDL treated, and 2 LDL-/- treated).
  • mice CXCL1 Abeam, Cat. No. ab 100717
  • mouse CXCL2 Abeam, Cat. No. ab204517
  • mouse CXCL3 Abeam, Cat. No. ab206310
  • mouse CXCL4 Abeam, Cat. No. abl00735
  • mouse IL-6 R&D Systems, Cat. No. M6000B
  • mouse IL-lb Abeam, Cat. No.
  • abl97742 mouse CXCL7 (Abeam, Cat. No. abl00742) in various experiments as noted in the text.
  • a Welch's t-test was used when 2 groups were compared, and a Dunn's Kruskal-Wallis test for multiple comparisons with Benjamini- Hochberg correction was used when 3 groups were being compared with the R package 'dunn.tesf (www.cran.r-project.org/web/packages/dunn.test/index.html).
  • cytokines/chemokines and receptors and focal adhesion genes including Col3al, Col4al, and Coll8al
  • the most significantly suppressed set contained genes involved in lysosomal function (including Lipa and Sortl) as shown on the left side of Figure 7B (Tables 7-8 and Figure 7B-C)
  • Tet2 and by LDL treatment were further studied.
  • Cxcll, Cxcl2, Cxcl3, Pf4, 116, and II lb transcript levels were among the most highly induced in Tet2-I- macrophages in this set
  • Cxcll, Cxcl2, Cxcl3, and Pf4 belong to a single C-X-C motif (CXC) chemokine gene cluster, while 116 and II lb are classic pro-inflammatory cytokine genes. Tet2-I- macrophages also secreted more of these proteins in vitro in response to LDL loading and/or endotoxin exposure than control macrophages, corroborating the increased level of messenger RNA. While either LDL or endotoxin (LPS) strongly induced the CXC chemokines, endotoxin but not LDL caused robust secretion of IL-lb and IL-6 ( Figure 9B). Therefore, the CXC chemokines may be the most relevant targets of modulation by Tet2 in atherosclerosis.
  • CXC C-X-C motif
  • CXC chemokine levels were measured in the transplanted mice after 13-17 weeks on diet.
  • Cxcll, Cxcl2, Cxcl3, Pf4, and Ppbp levels increased -2-4 fold in the serum of Ldlr-I- mice receiving Tet2-I- marrow (KO) compared to mice receiving control marrow (WT), while mice receiving Tet2+/- marrow (HET) showed intermediate levels (Figure 8B).
  • the CXC family chemokines were initially thought to selectively promote migration of neutrophils via the receptor CXCR2 (see Baggiolini M et al, FEES Lett 307:97-101 (1992)). However, in humans as well as mice, CXC
  • chemokine/CXCR2 interaction can also mediate firm monocyte adhesion to inflamed endothelium (see Gerszten RE et al, Nature 398:718-23 (1999) and Schwartz D et al, J Clin Invest 94: 1968-73 (1994)), and this interaction promotes atherogenesis (see Boisvert WA et al, J Clin Invest 101 :353-63 (1998) and Huo Y et al, J Clin Invest 108: 1307-14 (2001)).
  • ⁇ i Tet2 deficient macrophages caused accelerated atherosclerosis because of augmented production of monocyte and neutrophil chemoattractants, evidence of this may be seen in tissues beyond the vessel wall.
  • Transduced cells were sorted on the basis of GFP expression and frameshift mutations in TET2 were confirmed by sequencing.
  • the CRISPR-edited cells were then exposed to E. coli derived LPS (100 ng/mL for 1 x 10e cells) for 24 hours.
  • Chemokines secreted into the media were measured using ELISA. Results shown are total amount of chemokine secreted into media from 1 x 106 cells.
  • cells with engineered TET2 mutations produced nearly twice as much IL-8 and CXCL2. ( Figure 10).
  • Example 9 Loss of Dnmt3a function in myeloid cells enhances atherosclerosis in mice and alters macrophage inflammatory gene expression in vitro
  • Dnmt3a loss promotes atherogenesis was studied.
  • Dnmt3a catalyzes cytosine methylation of DNA, an epigenetic modification that can influence gene transcription. Therefore, Dnmt3a may modulate gene expression in macrophages in response to environmental stimuli such as excess cholesterol.
  • BMDM Bone marrow-derived macrophages
  • IMDM Iscove's Modification of DMEM
  • FBS fetal bovine serum
  • MCSF mouse macrophage colony stimulating factor
  • PSG penicillin/streptomycin/glutamine
  • BMDM were treated with LDL or vehicle as described above and harvested after 24h using Trizol reagent (Invitrogen, Cat. No. 15596026). RNA was purified using RNeasy Mini columns (Qiagen, Cat. No. 74104) followed by DNase treatment (TURBO DNA-free Kit, Life Technologies, Cat. No. AM 1907).
  • Ribo-Zero Kit (Illumina, Cat. No. MRZH116) was used to eliminate ribosomal RNA.
  • Library preparation using poly -A selection, multiplexing, and sequencing were done by Broad Institute (Cambridge, MA). A total of 11 samples were sequenced (3 Dnmt3a+/+ untreated, 3 Dnmt3a-/- untreated, 2 Dnmt3a+/+ LDL treated, and 3 Dnmt3a-I- LDL-/- treated).
  • mice CXCL1 Abeam, Cat. No. ab 100717
  • mouse CXCL2 Abeam, Cat. No. ab204517
  • mouse CXCL3 Abeam, Cat. No. ab206310
  • mouse IL-6 R&D Systems, Cat. No. M6000B
  • mouse IL-lb Abeam, Cat. No. abl97742
  • Cxcll, Cxcl2, Cxcl3, 116, and Illb transcript levels were among the most highly induced in Dnmt3a -I- macrophages in this set ( Figures 13- 15).
  • Cxcll, Cxcl2, and Cxcl3 belong to a single C-X-C motif (CXC) chemokine gene cluster, while 116, and Illb are classic pro-inflammatory cytokine genes.
  • Tet2-I- macrophages also secreted more of these proteins in vitro in response to LDL loading, corroborating the increased level of messenger RNA. ( Figure 15). Therefore, these chemokines and cytokines may be relevant targets in atherosclerosis due to DNMT 3 A mutations.
  • mice receiving 10% Dnmt3a-/- cells had a lesion size that was 40% larger than mice receiving control cells.
  • C-D Representative oil red O aortic root sections are shown for mice receiving only wild-type bone marrow (WT), or 10% Dnmt3a-/- bone marrow (10% KO).
  • Item 1 A method of treating atherosclerosis in a human subject comprising administering an effective amount of at least one IL-8 inhibitor, IL-6 inhibitor, and/or IL- ⁇ inhibitor, wherein the subject has a TET2 mutation and/or a DNMT3A mutation, thereby treating atherosclerosis.
  • Item 2 A method for treating atherosclerosis in a human subject comprising:
  • sequencing at least a part of a genome comprising TET2 and/or DNMT3A of one or more cells in a blood sample of the subject;
  • Item 3 A method of treating atherosclerosis in a human subject comprising administering an effective amount of at least one IL-8 inhibitor, wherein the subject's plasma IL-8 level is at least 20 ng/mL thereby treating atherosclerosis.
  • Item 4 A method for treating atherosclerosis in a human subject comprising:
  • Item 5 The method of any one of items 1-4, further comprising administering an effective amount of at least one cholesterol-lowering medication to the subject.
  • Item 6 The method of any one of items 1-5, further comprising prescribing exercise, cessation of smoking, diet modification, and/or stress reduction to the subject.
  • Item 7 A method for diagnosing atherosclerosis in a human subject comprising:
  • Item 8 The method of item 7, further comprising:
  • Item 9 A method of detecting at least one TET2 and/or DNMT3A mutation along with an increase in plasma level of IL-8 in a human subject comprising:
  • Item 10 The method of any one of items 1-9, wherein the at least one
  • TET2 and/or DNMT3A mutation comprises a frameshift mutation, nonsense mutation, missense mutation, or splice-site variant mutation.
  • Item 11 The method of any one of items 1-10, wherein the at least one
  • TET2 and/or DNMT3A mutation comprises at least one loss-of-function TET2 and/or
  • Item 12 The method of any one of items 10-11, wherein the mutation in
  • TET2 results in an amino acid change in TET2 chosen from S145N, S282F, A308T, N312S, L346P, P399L, S460F, D666G, S817T, P941 S, C1135Y, R1167T, I1175V, S 1204C, R1214W, D1242R, D1242V, Y1245S, R1261C, R1261H, R1261L, F1287L, W1291R, K1299E, K1299N, R1302G, E1318G, P1367S, C1396W, L1398R, V1417F, G1869W, L1872P, I1873T, C1875R, H1881Q, H1881R, R1896M, R1896S, S1898F, V1900A, G1913D, A1919V, R1926H, P1941 S, P1962L, R1966H, R1974M,
  • Item 13 The method of any one of items 10-12, wherein the mutation in
  • DNMT3A results in an amino acid change in DNMT3A chosen from F290I, F290C, V296M, P307S, P307R, R326H, R326L, R326C, R326S, G332R, G332E, V339A, V339M, V339G, L344Q, L344P, R366P, R366H, R366G, A368T, A368V, R379H, R379C, I407T, I407N, I407S, F414L, F414S, F414C, A462V, K468R, C497G, C497Y, Q527H, Q527P, Y533C, S535F, C537G, C537R, G543A, G543S, G543C, L547H, L547P, L547F, M548I, M548K, G
  • Item 14 The method of any one of items 1-13, wherein the human subject has at least one somatic blood cell clone with one mutant TET2 allele and one wildtype TET2 allele.
  • Item 15 The method of any one of items 1-13, wherein the human subject has at least one somatic blood cell clone with two mutant TET2 alleles.
  • Item 16 The method of any one of items 1-15, wherein the human subject has at least one somatic blood cell clone with one mutant DNMT3A allele and one wildtype DNMT3A allele.
  • Item 17 The method of any one of items 1-15, wherein the human subject has at least one somatic blood cell clone with two mutant DNMT3A alleles.
  • Item 18 The method of any one of items 1-17, wherein the human subject has clonal hematopoiesis of indeterminate potential (CHIP).
  • Item 19 The method of any one of items 1-18, wherein the human subject has at least one TET2 and/or DNMT3A mutation with a variant allele fraction of at least 2%, 5%, 10%, 13.5%, 15%, 20%, 25%, 27%, 30%.
  • Item 20 The method of any one of items 1-19, wherein the subject's plasma level of IL-8 is at least 25 ng/mL, 30 ng/mL, 40 ng/mL, 45 ng/mL, 50 ng/mL, 55 ng/mL, 60 ng/mL, 65 ng/mL, 70 ng/mL, 75 ng/mL, or 80 ng/mL.
  • Item 21 The method of any one of items 1-6 or 10-20, wherein the at least one IL-6 inhibitor and/or IL- ⁇ inhibitor is methotrexate.
  • Item 22 The method of item 21, wherein the methotrexate is administered at a dose of from 15 to 20 mg/week.
  • Item 23 The method of any one of items 1-6 or 10-22, wherein the at least one IL-8 inhibitor is an IL-8 depleting drug.
  • Item 24 The method of any one of items 1-6 or 10-23, wherein the at least one IL-8 inhibitor is an IL-8 activity reducing drug.
  • Item 25 The method of any one of items 1-6 or 10-24, wherein the at least one IL-8 inhibitor comprises an anti-IL-8 antibody or an antigen binding fragment thereof.
  • Item 26 The method of item 25, wherein the anti-IL-8 antibody or antigen binding fragment thereof comprises HuMaxIL-8, HuMab-10F8, or an antigen binding fragment thereof.
  • Item 27 The method of any one of items 1-6 or 10-26, wherein the at least one IL-8 inhibitor is an inhibitor of the IL-8 receptor CXCR2.
  • Item 28 The method of item 27, wherein the at least one IL-8 inhibitor comprises an anti-CXCR2 antibody or an antigen binding fragment thereof.
  • Item 29 The method of item 27, wherein the at least one IL-8 inhibitor comprises the CXCR2 inhibitor SB-332235 (GlaxoSmithKline) or the CXCR2 antagonist AZD5069 (AstraZeneca).
  • Item 30 The method of any one of items 1-6 or 10-29, wherein the IL-6 inhibitor is an IL-6 depleting drug.
  • Item 31 The method of any one of items 1-6 or 10-30, wherein the IL-6 inhibitor is an IL-6 activity reducing drug.
  • Item 32 The method of any one of items 1-6 or 10-31, wherein the IL-6 inhibitor comprises an anti-IL-6 antibody or an antigen binding fragment thereof.
  • Item 33 The method of item 32, wherein the anti-IL-6 antibody or antigen binding fragment thereof comprises siltuximab, olokizumab, elsilimomab, mAb 1339, BMS-945429, sirukumab, CPSI-2364, ALX-0061, clazakizumab, ARGX-109, MEDI5117, FE301, FM101, or C326.
  • Item 34 The method of any one of items 1-6 or 10-31, wherein the at least one IL-6 inhibitor is an inhibitor of the IL-6 receptor IL-6R or an inhibitor of gpl30.
  • Item 35 The method of item 34, wherein the inhibitor of IL-6R comprises tocilizumab or sarilumab.
  • Item 36 The method of any one of items 1-6 or 10-31, wherein the IL-6 inhibitor comprises tamibarotene or ATRA.
  • Item 37 The method of any one of items 1-6 or 10-36, wherein the IL- ⁇ inhibitor is an IL- ⁇ depleting drug.
  • Item 38 The method of any one of items 1-6 or 10-37, wherein the IL- ⁇ inhibitor is an IL- ⁇ activity reducing drug.
  • Item 39 The method of any one of items 1-6 or 10-38, wherein the IL- ⁇ inhibitor comprises an anti- IL- ⁇ ⁇ antibody or antigen binding fragment thereof.
  • Item 40 The method of any one of items 1-6 or 10-39, wherein the anti-
  • IL- ⁇ antibody or antigen binding fragment thereof comprises canakinumab.
  • Item 41 The method of any one of items 1 -6 or 10-38, wherein the IL- 1 ⁇ inhibitor is an inhibitor of the IL- ⁇ receptor.
  • Item 42 The method of any one of items 1 -6 or 10-38, wherein the IL- 1 ⁇ inhibitor is an inhibitor of IL-1 receptor.
  • Item 43 The method of item 42, wherein the inhibitor of the IL-1 receptor is anakinra.
  • Item 44 The method of any one of items 5-6 and 10-43, wherein at least one cholesterol-lowering medication comprises at least one PCSK9 inhibitor, at least one statin, at least one selective cholesterol absorption inhibitor, at least one resin, at least one lipid- lowering therapy, at least one CETP inhibitor, at least one pantothenic acid derivative, at least one microsomal triglyceride transfer protein (MTP) inhibitor, at least one adenosine
  • at least one cholesterol-lowering medication comprises at least one PCSK9 inhibitor, at least one statin, at least one selective cholesterol absorption inhibitor, at least one resin, at least one lipid- lowering therapy, at least one CETP inhibitor, at least one pantothenic acid derivative, at least one microsomal triglyceride transfer protein (MTP) inhibitor, at least one adenosine
  • MTP microsomal triglyceride transfer protein
  • triphosphate-binding cassette transporter Al (ABCAl)-promoter, aspirin, estrogen, and/or at least one lipoprotein complex.
  • Item 45 The method of item 44, wherein the cholesterol-lowering medication comprises at least one PCSK9 inhibitor.
  • Item 46 The method of item 45, wherein the PCSK9 inhibitor is chosen from at least one of (i) an anti-PCSK9 antibody or antigen-binding fragment thereof, (ii) an antisense or RNAi therapeutic agent that inhibits the synthesis of PCSK9, (ii) a PCSK9-targeting vaccine.
  • the PCSK9 inhibitor is chosen from at least one of (i) an anti-PCSK9 antibody or antigen-binding fragment thereof, (ii) an antisense or RNAi therapeutic agent that inhibits the synthesis of PCSK9, (ii) a PCSK9-targeting vaccine.
  • Item 47 The method of item 46, wherein the anti-PC SK9 antibody or antigen-binding fragment thereof is evolocumab, alirocumab, bococizumab, LGT209, RG7652, or LY3015014.
  • Item 48 The method of item 46, wherein the RNAi therapeutic agent that inhibits the synthesis of PCSK9 is inclisiran.
  • Item 49 The method of item 46, wherein the PCSK9-targeting vaccine is
  • Item 50 The method of item 45, wherein the PCSK9 inhibitor is a polypeptide that binds PCSK9 (such as adnectin).
  • Item 51 The method of item 45, wherein the PCSK9 inhibitor is a locked nucleic acid targeting PCSK9 (such as SPC5001).
  • the PCSK9 inhibitor is a locked nucleic acid targeting PCSK9 (such as SPC5001).
  • Item 52 The method of item 46, wherein the PCSK9 inhibitor is an antisense RNA that inhibits the synthesis of PCSK9 is ISIS-405879/BMS-844421.
  • Item 53 The method of item 45, wherein the cholesterol-lowering medication comprises at least one statin.
  • Item 54 The method of item 53, wherein the statin is chosen from at least one of atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and pitavastatin.
  • Item 55 The method of item 53, wherein the statin comprises a combination therapy chosen from (i) lovastatin and niacin, (ii) atorvastatin and amlodipine, and (iii) simvastatin and ezetimibe.
  • a combination therapy chosen from (i) lovastatin and niacin, (ii) atorvastatin and amlodipine, and (iii) simvastatin and ezetimibe.
  • Item 56 The method of item 44, wherein the cholesterol-lowering medication comprises at least one selective cholesterol absorption inhibitor.
  • Item 57 The method of item 56, wherein the selective cholesterol absorption inhibitor is ezetimibe.
  • Item 58 The method of item 44, wherein the cholesterol-lowering medication comprises at least one resin.
  • Item 59 The method of item 58, wherein the resin is chosen from cholestyramine, colestipol, and colesevelam.
  • Item 60 The method of item 44, wherein the cholesterol-lowering medication comprises at least one lipid-lowering therapy.
  • Item 61 The method of item 60, wherein the lipid-lowering therapy is chosen from at least one fibrate, niacin, and at least one omega-3 fatty acid.
  • Item 62 The method of item 60, wherein the lipid-lowering therapy comprises at least one fibrate.
  • Item 63 The method of item 62, wherein the fibrate is chosen from gemfibrozil, fenofibrate, and clofibrate.
  • Item 64 The method of item 60, wherein the lipid-lowering therapy comprises at least one omega-3 fatty acid.
  • Item 65 The method of item 64, wherein the omega-3 fatty acid is chosen from at least one of omega-3 fatty acid ethyl esters and omega-3 polyunsaturated fatty acids.
  • Item 66 The method of item 65, wherein the omega-3 fatty acid ethyl esters are icosapent ethyl.
  • Item 67 The method of item 65, wherein the omega-3 polyunsaturated fatty acids are marine-derived omega-3 polyunsaturated fatty acids.
  • Item 68 The method of item 44, wherein the cholesterol-lowering medication comprises a CETP inhibitor.
  • Item 69 The method of item 68, wherein the CETP inhibitor is chosen from at least one of anacetrapib and obicetrapib.
  • Item 70 The method of item 44, wherein the cholesterol-lowering medication comprises at least one MTP inhibitor.
  • Item 71 The method of item 70, wherein the MTP inhibitor is chosen from at least one of (i) a small molecule that inhibits function of MTP, (ii) an RNAi therapeutic agent that inhibits the synthesis of MTP, and (iii) an antisense RNA that inhibits synthesis of MTP.
  • the MTP inhibitor is chosen from at least one of (i) a small molecule that inhibits function of MTP, (ii) an RNAi therapeutic agent that inhibits the synthesis of MTP, and (iii) an antisense RNA that inhibits synthesis of MTP.
  • Item 72 The method of item 71, wherein the small molecule that inhibits function of MTP is chosen from at least one of lomitapide, JTT-130, Slx-4090, and dirlotapide.
  • Item 73 The method of item 44, wherein the cholesterol-lowering medication comprises adenosine triphosphate-binding cassette transporter Al (ABCA1)- promoter.
  • ABCA1 adenosine triphosphate-binding cassette transporter Al
  • Item 74 The method of item 73, wherein the adenosine triphosphate- binding cassette transporter Al (ABCAl)-promoting drug is chosen from at least one of (i) an apoA-1 mimetic peptide, (ii) a full-length apoA-1, and (iii) a reconstituted HDL.
  • ABCAl adenosine triphosphate- binding cassette transporter Al
  • Item 75 The method of item 74, wherein the apoA-1 mimetic peptide is
  • FAMP type 5 FAMP5
  • Item 76 The method of item 74, wherein the full-length apoA-1 is ApoA-
  • Item 77 The method of item 44, wherein the cholesterol-lowering medication comprises estrogen.
  • Item 78 The method of item 44, wherein the cholesterol-lowering medication comprises at least one lipoprotein complex.
  • Item 79 The method of item 78, wherein the lipoprotein complex is chosen from at least one of CER-001, CSL-111, CSL-112, and ETC-216.
  • Item 80 The method of item 78, wherein the lipoprotein complex is chosen from at least one of apolipoprotein or apolipoprotein peptide mimic.
  • Item 81 The method of item 80, wherein the (i) apolipoprotein is chosen from at least one of ApoA-I, ApoA-II, ApoA-IV, and ApoE and/or (ii) the peptide mimetic is chosen from at least one of ApoA-I, ApoA-II, ApoA-IV, and ApoE peptide mimic.
  • Item 82 The method of any one of items 1-81, wherein the human subject also exhibits one or more risk factors of being a smoker, having level of total cholesterol of at least 200 mg/dL, or having level of low-density lipoprotein (LDL) of at least 130 mg/dL.
  • LDL low-density lipoprotein
  • Item 83 The method of item 82, wherein the human subject has a total cholesterol of at least 240 mg/dL and/or an LDL of at least 160 mg/dL.
  • Item 84 The method of any one of items 1-83, wherein the human subject has an hsCRP level of at least 2 mg/L.
  • Item 85 The method of any one of items 6 and 10-84, wherein the method comprises prescribing exercise.
  • Item 86 The method of item 85, wherein the method comprises prescribing exercise for at least 3, 4, 5, 6, or 7 days a week.
  • Item 87 The method of any one of items 85-86, wherein the method comprises prescribing cardiovascular conditioning exercise.
  • Item 88 The method of any one of item 85-87, wherein the method comprises prescribing strength training exercise.
  • Item 89 The method of any one of items 6 and 10-88, wherein the method comprises prescribing cessation of smoking.
  • Item 90 The method of item 89, wherein the method comprises administering a medication to support smoking cessation.
  • Item 91 The method of item 90, wherein the medication to support smoking cessation is chosen from at least one of nicotine replacement therapy, antidepressants (such as bupropion, nortriptyline, or an SSRI), varenicline, and clonidine.
  • antidepressants such as bupropion, nortriptyline, or an SSRI
  • Item 92 The method of any one of items 6 and 10-91, wherein the method comprises diet modification.
  • Item 93 The method of item 92, wherein the diet modification is chosen from at least one of a reduction in fat consumption, a reduction in cholesterol consumption, a reduction in sugar consumption, an increase in fruit and/or vegetable consumption, an increase in omega fatty acids, and/or reduction of alcohol consumption.
  • Item 94 The method of any one of items 6 and 10-93, wherein the method comprises stress reduction.
  • Item 95 The method of item 94, wherein the stress reduction is chosen from at least one of relaxation techniques, mediation, breathing exercises, exercise, and/or anger management.
  • Item 96 The method of any one of items 6 and 10-95, wherein the method comprises prescribing psychiatric medication.
  • Item 97 The method of item 96, wherein the method comprises antianxiety medication and/or anti-depressant medication.
  • Item 98 The method of item 97, wherein the anti-anxiety medication and/or anti-depressant medication is chosen from at least one of citalopram, escitalopram, fluoxetine, paroxetine, sertraline, duloxetine, venlafaxine, imipramine, hydroxyzine, propanolol, gabapentin, and pregabalin.
  • the anti-anxiety medication and/or anti-depressant medication is chosen from at least one of citalopram, escitalopram, fluoxetine, paroxetine, sertraline, duloxetine, venlafaxine, imipramine, hydroxyzine, propanolol, gabapentin, and pregabalin.
  • Item 99 The method of any one of items 6 and 10-98, wherein the method comprises prescribing psychological counseling.
  • Item 100 The method of any one of items 1-99, wherein a TET2 and/or
  • DNMT3A mutation is identified by whole exome sequencing (WES).
  • Item 101 The method of any one of items 1-100, wherein a TET2 and/or
  • DNMT3A mutation is identified by sequencing DNA.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement de l'athérosclérose chez un sujet humain comprenant l'administration d'une quantité efficace d'un inhibiteur de l'IL-8, d'un inhibiteur de l'IL-6, et/ou d'un inhibiteur de l'IL-1β, le sujet présentant une mutation de TET2 et/ou de DNMT3A, ce qui permet de traiter l'athérosclérose. L'invention concerne également une méthode de traitement de l'athérosclérose chez un sujet humain consistant à séquencer au moins une partie d'un génome comprenant TET2 et/ou DNMT3A d'une ou plusieurs cellules dans un échantillon de sang du sujet ; déterminer à partir du séquençage si le sujet présente une ou plusieurs mutations dans TET2 et/ou DNMT3A, s'il est déterminé que le sujet présente au moins une mutation de TET2 et/ou de DNMT3A, administrer au sujet un inhibiteur de l'IL-8, un inhibiteur de l'IL-6 et/ou un inhibiteur de l'IL-1β, ce qui permet de traiter l'athérosclérose.
PCT/US2018/029098 2017-04-25 2018-04-24 Il-8, il-6, il-1b et tet2 et dnmt3a dans l'athérosclérose WO2018200489A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/606,928 US20200131576A1 (en) 2017-04-25 2018-04-24 IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis
EP18727474.1A EP3615694B1 (fr) 2017-04-25 2018-04-24 Il-8, il-6, il-1b et tet2 et dnmt3a dans l'athérosclérose

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762489823P 2017-04-25 2017-04-25
US62/489,823 2017-04-25
US201762567735P 2017-10-03 2017-10-03
US62/567,735 2017-10-03

Publications (1)

Publication Number Publication Date
WO2018200489A1 true WO2018200489A1 (fr) 2018-11-01

Family

ID=62245401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/029098 WO2018200489A1 (fr) 2017-04-25 2018-04-24 Il-8, il-6, il-1b et tet2 et dnmt3a dans l'athérosclérose

Country Status (3)

Country Link
US (1) US20200131576A1 (fr)
EP (1) EP3615694B1 (fr)
WO (1) WO2018200489A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220275079A1 (en) * 2020-11-20 2022-09-01 The General Hospital Corporation Clonal Hematopoiesis and Risk of Chronic Liver Disease

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4202061A4 (fr) * 2020-08-20 2024-09-11 Genome Opinion Inc Biomarqueur pour le diagnostic d'une dégénérescence maculaire liée à l'âge et utilisation associée
KR102572356B1 (ko) * 2021-04-15 2023-08-30 (주)지놈오피니언 혈액세포 돌연변이 정보를 이용한 죽상동맥경화성 심뇌혈관질환의 위험도 예측 방법

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446603A (en) 1993-12-21 1995-08-29 Dictaphone Corporation Method of retrieving messages at selected times from a digital audio tape
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5989431A (en) 1995-06-08 1999-11-23 Progen Industries Ltd Method and apparatus for DNA extraction
US6114122A (en) 1996-03-26 2000-09-05 Affymetrix, Inc. Fluidics station with a mounting system and method of using
US6238910B1 (en) 1998-08-10 2001-05-29 Genomic Solutions, Inc. Thermal and fluid cycling device for nucleic acid hybridization
WO2001045843A2 (fr) 1999-12-22 2001-06-28 Gene Logic, Inc. Cartouche de puce a ecoulement continu, porte-puce, systeme et son procede
US6365418B1 (en) 1998-07-14 2002-04-02 Zyomyx, Incorporated Arrays of protein-capture agents and methods of use thereof
US6410229B1 (en) 1995-09-15 2002-06-25 Affymetrix, Inc. Expression monitoring by hybridization to high density nucleic acid arrays
US6420114B1 (en) 1999-12-06 2002-07-16 Incyte Genomics, Inc. Microarray hybridization chamber
US6489159B1 (en) 1998-01-07 2002-12-03 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays
US6548256B2 (en) 2000-07-14 2003-04-15 Eppendorf 5 Prime, Inc. DNA isolation method and kit
US20040208873A1 (en) * 2002-12-16 2004-10-21 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
WO2009120186A1 (fr) * 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Procédés et compositions pour traiter l'athérosclérose et des états associés
WO2010045346A1 (fr) * 2008-10-14 2010-04-22 University Of Miami Analyse d’expression pour le dépistage de l’athérosclérose coronarienne
US20120294852A1 (en) 2009-11-24 2012-11-22 Smith Jeffrey T L Antagonists of il-6 to raise albumin and/or lower crp
WO2012163589A1 (fr) * 2011-05-27 2012-12-06 Unilever Plc Composition de polyphénols destinée à la prévention ou au traitement de l'athérosclérose
US20130136726A1 (en) * 2010-05-19 2013-05-30 Mas-Metabolic Analytical Services Oy Method for detection of predisposition to atherosclerosis, coronary heart disease and related conditions
US20150140002A1 (en) 2013-10-11 2015-05-21 Sanofi Use of a pcsk9 inhibitor to treat hyperlipidemia
WO2016086197A1 (fr) * 2014-11-25 2016-06-02 The Brigham And Women's Hospital, Inc. Méthode d'identification et de traitement d'une personne présentant une prédisposition à souffrir ou souffrant d'une maladie cardiométabolique
US20160377632A1 (en) * 2007-02-05 2016-12-29 Region Nordjylland Method for diganosing atherosclerotic plaques by measurement of cd36

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9297046B2 (en) * 2008-06-12 2016-03-29 Assistance Publique—Hopitaux de Paris TET2 as a new diagnostic and pronostic marker in hematopoietic neoplasms

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5446603A (en) 1993-12-21 1995-08-29 Dictaphone Corporation Method of retrieving messages at selected times from a digital audio tape
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5874219A (en) 1995-06-07 1999-02-23 Affymetrix, Inc. Methods for concurrently processing multiple biological chip assays
US5989431A (en) 1995-06-08 1999-11-23 Progen Industries Ltd Method and apparatus for DNA extraction
US6410229B1 (en) 1995-09-15 2002-06-25 Affymetrix, Inc. Expression monitoring by hybridization to high density nucleic acid arrays
US6114122A (en) 1996-03-26 2000-09-05 Affymetrix, Inc. Fluidics station with a mounting system and method of using
US6489159B1 (en) 1998-01-07 2002-12-03 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays
US6475808B1 (en) 1998-07-14 2002-11-05 Zyomyx, Incorporated Arrays of proteins and methods of use thereof
US6365418B1 (en) 1998-07-14 2002-04-02 Zyomyx, Incorporated Arrays of protein-capture agents and methods of use thereof
US6432696B2 (en) 1998-08-10 2002-08-13 Genomic Solutions, Inc. Thermal and fluidic cycling device for nucleic acid hybridization
US6238910B1 (en) 1998-08-10 2001-05-29 Genomic Solutions, Inc. Thermal and fluid cycling device for nucleic acid hybridization
US6420114B1 (en) 1999-12-06 2002-07-16 Incyte Genomics, Inc. Microarray hybridization chamber
WO2001045843A2 (fr) 1999-12-22 2001-06-28 Gene Logic, Inc. Cartouche de puce a ecoulement continu, porte-puce, systeme et son procede
US6548256B2 (en) 2000-07-14 2003-04-15 Eppendorf 5 Prime, Inc. DNA isolation method and kit
US20040208873A1 (en) * 2002-12-16 2004-10-21 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
US20160377632A1 (en) * 2007-02-05 2016-12-29 Region Nordjylland Method for diganosing atherosclerotic plaques by measurement of cd36
WO2009120186A1 (fr) * 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Procédés et compositions pour traiter l'athérosclérose et des états associés
WO2010045346A1 (fr) * 2008-10-14 2010-04-22 University Of Miami Analyse d’expression pour le dépistage de l’athérosclérose coronarienne
US20120294852A1 (en) 2009-11-24 2012-11-22 Smith Jeffrey T L Antagonists of il-6 to raise albumin and/or lower crp
US20130136726A1 (en) * 2010-05-19 2013-05-30 Mas-Metabolic Analytical Services Oy Method for detection of predisposition to atherosclerosis, coronary heart disease and related conditions
WO2012163589A1 (fr) * 2011-05-27 2012-12-06 Unilever Plc Composition de polyphénols destinée à la prévention ou au traitement de l'athérosclérose
US20150140002A1 (en) 2013-10-11 2015-05-21 Sanofi Use of a pcsk9 inhibitor to treat hyperlipidemia
WO2016086197A1 (fr) * 2014-11-25 2016-06-02 The Brigham And Women's Hospital, Inc. Méthode d'identification et de traitement d'une personne présentant une prédisposition à souffrir ou souffrant d'une maladie cardiométabolique

Non-Patent Citations (45)

* Cited by examiner, † Cited by third party
Title
"ATVB Italian Study Group", CIRCULATION, vol. 107, 2003, pages 1117 - 22
ABRAM CL ET AL., J IMMUNOL METHODS, vol. 408, 2014, pages 89 - 100
ALTSCHUL ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 215, 1990, pages 403 - 410
BABER U ET AL., JAM COLL CARDIOL, vol. 65, 2015, pages 1065 - 74
BAGGIOLINI M ET AL., FEBS LETT, vol. 307, 1992, pages 97 - 101
BERGLUND G ET AL., J INTERN MED, vol. 233, 1993, pages 45 - 51
BOISVERT WA ET AL., J CLIN INVEST, vol. 101, 1998, pages 353 - 63
CAVUSOGLU ERDAL ET AL: "Elevated baseline plasma IL-8 levels are an independent predictor of long-term all-cause mortality in patients with acute coronary syndrome", ATHEROSCLEROSIS, ELSEVIER, AMSTERDAM, NL, vol. 242, no. 2, 17 August 2015 (2015-08-17), pages 589 - 594, XP029271880, ISSN: 0021-9150, DOI: 10.1016/J.ATHEROSCLEROSIS.2015.08.022 *
CIBULSKIS K ET AL., NAT BIOTECHNOL, vol. 31, 2013, pages 213 - 9
DEPRISTO MA ET AL., NATURE GENETICS, vol. 43, 2011, pages 491 - 8
DO R ET AL., NATURE, vol. 518, 2015, pages 102 - 6
DOOLITTLE: "Methods in Enzymology", vol. 266, 1996, article ALTSCHUL; GISH: "Local alignment statistics", pages: 460 - 480, XP000857701, DOI: doi:10.1016/S0076-6879(96)66029-7
ELIAS-SMALE SE ET AL., JAM COLL CARDIOL, vol. 56, 2010, pages 1407 - 14
FEINLEIB M ET AL., PREV MED, vol. 4, 1975, pages 518 - 25
GENOVESE G ET AL., N ENGL JMED, vol. 371, 2014, pages 2477 - 87
GERSZTEN RE ET AL., NATURE, vol. 398, 1999, pages 718 - 23
GISH; STATES, NATURE GENETICS, vol. 3, 1993, pages 266 - 272
HIROTA ET AL., JINRUI IDENGAKU ZASSHI, vol. 34, no. 3, September 1989 (1989-09-01), pages 217 - 23
HU L ET AL., CELL, vol. 155, 2013, pages 1545 - 55
HUO Y ET AL., J CLIN INVEST, vol. 108, 2001, pages 1307 - 14
ISHIBASHI S ET AL., J CLIN INVEST, vol. 92, 1993, pages 883 - 93
JAISWAL S ET AL., NENG J MED, vol. 371, 2014, pages 2488 - 98
JOHN ET AL., NUCLEIC ACIDS RES., vol. 19, no. 2, 25 January 1991 (1991-01-25), pages 408
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877
KATHIRESAN S ET AL., N ENGL J MED, vol. 358, 2008, pages 1240 - 9
KRUTH HS, CURR OPIN LIPIDOL, vol. 22, 2011, pages 386 - 93
LI H ET AL., BIOINFORMATICS, vol. 25, 2009, pages 1754 - 60
MORAN-CRUSIO K ET AL., CANCER CELL, vol. 20, 2011, pages 11 - 24
MUNTENDAM P ET AL., AM HEART J, vol. 160, 2010, pages 49 - 57
MUNTENDAM P ET AL., AM HEART J, vol. 160, 2010, pages 49057 el
MYERS; MILLER, CABIOS, vol. 4, 1988, pages 11 - 17
PAUL M RIDKER ET AL: "Interleukin-1 inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)", AMERICAN HEART JOURNAL, ELSEVIER, AMSTERDAM, NL, vol. 162, no. 4, 20 June 2011 (2011-06-20), pages 597 - 605, XP028308077, ISSN: 0002-8703, [retrieved on 20110623], DOI: 10.1016/J.AHJ.2011.06.012 *
PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444 - 2448
PSATY BM ET AL., CIRC CARDIOVASC GENET, vol. 2, 2009, pages 73 - 80
ROSS R, N ENGL J MED, vol. 340, 1999, pages 115 - 26
SANADA M ET AL., NATURE, vol. 460, 2009, pages 904 - 8
SCHWARTZ D ET AL., J CLIN INVEST, vol. 94, 1994, pages 1968 - 73
SEMPOS CT ET AL., AM J MED SCI, vol. 317, 1999, pages 142 - 6
SMITH EB ET AL., EUR HEART J, vol. 11, 1990, pages 72 - 81
SPLANSKY, AM J EPIDEMIOL, vol. 165, 2007, pages 1328 - 35
TAHILIANI M ET AL., SCIENCE, vol. 324, 2009, pages 930 - 5
TENNESSEN JA ET AL., SCIENCE, vol. 337, 2012, pages 64 - 9
VALLE T ET AL., DIABETES CARE, vol. 21, 1998, pages 949 - 58
WILBUR; LIPMAN, PROC NATL ACAD SCI USA, vol. 80, 1983, pages 726

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220275079A1 (en) * 2020-11-20 2022-09-01 The General Hospital Corporation Clonal Hematopoiesis and Risk of Chronic Liver Disease

Also Published As

Publication number Publication date
EP3615694B1 (fr) 2022-03-30
US20200131576A1 (en) 2020-04-30
EP3615694A1 (fr) 2020-03-04

Similar Documents

Publication Publication Date Title
US10329354B2 (en) Modulation of efferocytosis pathways for treatment of atherosclerotic disease
Wang et al. Systems analysis of eleven rodent disease models reveals an inflammatome signature and key drivers
US9782389B2 (en) Fungal mycobiome as probiotics, diagnostics and therapeutics
EP3811972B1 (fr) Thérapie combinée pour le traitement de l'athérosclérose
McPherson et al. Inflammation and coronary artery disease: insights from genetic studies
WO2019070755A1 (fr) Procédés et compositions pour détecter et moduler une signature génétique de résistance à l'immunothérapie dans un cancer
Savva et al. Impact of Toll‐like receptor‐4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa
Zorzetto et al. Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis
US20060099610A1 (en) Method and kit for detecting a risk of acute myocardial infarction
EP3615694B1 (fr) Il-8, il-6, il-1b et tet2 et dnmt3a dans l'athérosclérose
CN114828890A (zh) 使用了干细胞迁移剂的糖尿病治疗
WO2007006862A2 (fr) Methode et trousse permettant de detecter un risque de coronaropathie
KR20140137444A (ko) 인간 림프 기관-유래 억제성 기질 세포의 분리 및 용도
Takaoka et al. Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis
KR20150016589A (ko) 염증-부여 폴리펩타이드 및 이의 용도
Shao et al. Atf3 coordinates the survival and proliferation of cardiac macrophages and protects against ischemia–reperfusion injury
US20050053956A1 (en) Detection of a predisposition for the development of coronary artery disease
JP5033392B2 (ja) ２型糖尿病の遺伝的リスク検出法
WO2019209640A1 (fr) Souche bactérienne isolée pour induire la prolifération ou l'accumulation de lymphocytes t régulateurs
de la Fuente-Munoz et al. Case Report: Novel STIM1 gain-of-function mutation in a patient with TAM/STRMK and immunological involvement
Mescheriakova et al. Genetics of multiple sclerosis
CN114828891A (zh) 以异常干细胞为靶标的糖尿病治疗
Van der Cruyssen et al. GDF15 mediates inflammation-associated bone loss through a brain-bone axis
Rajakumar Molecular Mechanisms of Bone Destruction and Central Nervous System Invasion in B Cell Acute Lymphoblastic Leukemia
Ria Role of the OX40 ligand/receptor pair in coronary artery disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18727474

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018727474

Country of ref document: EP

Effective date: 20191125